beta-alanine has been researched along with Bleeding in 299 studies
Excerpt | Relevance | Reference |
---|---|---|
"Warfarin and aspirin are used to prevent stroke in patients with atrial fibrillation (AF)." | 10.27 | Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. ( Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M, 2013) |
"The aim of this study was to compare the management and prognosis of major bleeding in patients treated with dabigatran or warfarin." | 10.27 | Management and outcomes of major bleeding during treatment with dabigatran or warfarin. ( Brueckmann, M; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Fraessdorf, M; Hwang, HG; Majeed, A; Schulman, S; Wallentin, L; Yusuf, S, 2013) |
"Dabigatran has similar effects on VTE recurrence and a lower risk of bleeding compared with warfarin for the treatment of acute VTE." | 9.19 | Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. ( Christiansen, AV; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Le Maulf, F; Mismetti, P; Peter, N; Schellong, S; Schulman, S, 2014) |
"We observed a rate of major bleeding similar to that reported in randomized clinical trials among patients with AF prescribed dabigatran or rivaroxaban." | 9.19 | Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting. ( Evans, RS; Fontaine, GV; Lloyd, JF; Mathews, KD; Stevens, SM; Woller, SC, 2014) |
"Dabigatran was effective in the extended treatment of venous thromboembolism and carried a lower risk of major or clinically relevant bleeding than warfarin but a higher risk than placebo." | 9.17 | Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. ( Baanstra, D; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Kvamme, AM; Mismetti, P; Schellong, S; Schulman, S, 2013) |
"In 18,113 AF patients in the RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) trial, we used a previously developed method for integrating ischemic and bleeding events as "ischemic stroke equivalents" in order to compare a weighted benefit of 2 doses of dabigatran with each other, and with that of warfarin." | 9.17 | Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. ( Connolly, SJ; Eikelboom, JW; Hart, RG; Oldgren, J; Reilly, P; Wallentin, L; Yang, S; Yusuf, S, 2013) |
"3 years of continued treatment with dabigatran after RE-LY, there was a higher rate of major bleeding with dabigatran 150 mg twice daily in comparison with 110 mg, and similar rates of stroke and death." | 9.17 | The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. ( Alings, M; Amerena, JV; Avezum, A; Baumgartner, I; Brueckmann, M; Budaj, AJ; Chen, JH; Connolly, SJ; Dans, AL; Darius, H; Di Pasquale, G; Duffy, CO; Eikelboom, J; Ezekowitz, MD; Ferreira, J; Flaker, GC; Flather, MD; Franzosi, MG; Golitsyn, SP; Halon, DA; Heidbuchel, H; Hohnloser, SH; Huber, K; Jansky, P; Kamensky, G; Keltai, M; Kim, SS; Lau, CP; Le Heuzey, JY; Lewis, BS; Liu, L; Nanas, J; Oldgren, J; Omar, R; Pais, P; Pedersen, KE; Piegas, LS; Pogue, J; Raev, D; Reilly, PA; Smith, PJ; Talajic, M; Tan, RS; Tanomsup, S; Themeles, E; Toivonen, L; Vinereanu, D; Wallentin, L; Wang, SQ; Xavier, D; Yusuf, S; Zhu, J, 2013) |
"The distribution of activated partial thromboplastin time (APTT) in nonvalvular atrial fibrillation (NVAF) patients under dabigatran therapy remains to be clarified." | 9.16 | Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time. ( Aizawa, T; Funada, R; Kirigaya, H; Koike, A; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Sawada, H; Suzuki, S; Uejima, T; Yajima, J; Yamashita, T, 2012) |
"Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required." | 9.16 | Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. ( Avezum, A; Connolly, SJ; Douketis, J; Eikelboom, J; Ezekowitz, M; Healey, JS; Heidbuchel, H; Heidbuchle, H; Oldgren, J; Reilly, P; Themeles, E; Wallentin, L; Yang, S; Yusuf, S, 2012) |
" The frequencies of stroke and major bleeding within 30 days of cardioversion on the 2 doses of dabigatran were low and comparable to those on warfarin with or without transesophageal echocardiography guidance." | 9.15 | Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. ( Aikens, TH; Brugada, J; Chernick, M; Connolly, SJ; Ezekowitz, MD; Flaker, G; Kamensky, G; Nagarakanti, R; Oldgren, J; Parekh, A; Reilly, PA; Yang, S; Yusuf, S, 2011) |
"RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) is an international multicenter study (18,113 patients from 967 centers in 44 countries) that demonstrated the ability of dabigatran to reduce the occurrence of both stroke and hemorrhage in patients who had atrial fibrillation (AF) with high risks of stroke compared with patients who received warfarin." | 9.15 | Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial. ( Connolly, SJ; Ezekowitz, MD; Hori, M; Reilly, PA; Wallentin, L; Yusuf, S, 2011) |
"After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel." | 9.15 | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011) |
"In patients with atrial fibrillation at risk for stroke, both doses of dabigatran compared with warfarin have lower risks of both intracranial and extracranial bleeding in patients aged <75 years." | 9.15 | Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. ( Alings, M; Connolly, SJ; Diener, HC; Eikelboom, JW; Ezekowitz, M; Franzosi, MG; Healey, JS; Hohnloser, SH; Huber, K; Kaatz, S; Oldgren, J; Reilly, P; Varrone, J; Wallentin, L; Yang, S; Yusuf, S, 2011) |
"To evaluate the prognostic importance of CHADS(2) risk score in patients with atrial fibrillation receiving oral anticoagulants, including the vitamin K antagonist warfarin and the direct thrombin inhibitor dabigatran." | 9.15 | Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. ( Alings, M; Connolly, SJ; Darius, H; Diener, HC; Eikelboom, J; Ezekowitz, MD; Kamensky, G; Oldgren, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S, 2011) |
"In October 2011, DTB reviewed the use of dabigatran, the first new oral anticoagulant licensed for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) and one or more defined risk factors." | 8.90 | {blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF. ( , 2014) |
"Since the approval of dabigatran etexilate, numerous case reports have suggested the potential dangers of bleeding complications, especially given that there is no known antidote." | 8.90 | Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population. ( Brunetti, L; Chen, C; White, J, 2014) |
"The primary objective was to assess the cost-effectiveness of new oral anticoagulants compared with warfarin in patients with nonvalvular atrial fibrillation." | 8.89 | Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. ( Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA, 2013) |
"Dabigatran is a direct inhibitor of thrombin that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation." | 8.88 | Preventing cardioembolic stroke in atrial fibrillation with dabigatran. ( Diener, HC; Eikelboom, JW; Hohnloser, SH; Weimar, C, 2012) |
"For patients with atrial fibrillation and a high risk of thrombosis, the standard prophylaxis is warfarin, an anticoagulant, at a dose adjusted to the INR." | 8.88 | Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients. ( , 2012) |
"New oral anticoagulant drugs are emerging as alternatives to warfarin for the prevention of stroke in patients with non-valvular atrial fibrillation." | 8.88 | An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. ( Ansell, J; Mantha, S, 2012) |
"In patients with NVAF at risk of stroke, the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial demonstrated that, compared with warfarin, dabigatran 150 mg b." | 8.88 | New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran. ( Barrios, V; Escobar, C, 2012) |
"Dabigatran and other new oral anticoagulants (OAC) represent a step forward in stroke prevention in patients with atrial fibrillation (AF)." | 8.87 | Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). ( Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Palareti, G; Pengo, V; Poli, D; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A, 2011) |
"The comparative safety of dabigatran versus warfarin for treatment of nonvalvular atrial fibrillation in general practice settings has not been established." | 7.81 | Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. ( Goulding, MR; Graham, DJ; Houstoun, M; Kelman, JA; Levenson, M; MaCurdy, TE; Mott, K; Reichman, ME; Sheu, TC; Southworth, MR; Wernecke, M; Worrall, C; Zhang, R, 2015) |
"It remains unclear whether dabigatran etexilate mesylate is associated with higher risk of bleeding than warfarin sodium in real-world clinical practice." | 7.81 | Risk of bleeding with dabigatran in atrial fibrillation. ( Baik, SH; Hernandez, I; Piñera, A; Zhang, Y, 2015) |
"Compared with warfarin, periprocedural anticoagulation with dabigatran resulted in fewer minor hemorrhages and total adverse events after AF ablation." | 7.81 | Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. ( Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD, 2015) |
"Prevalence plots were used to describe the point prevalence (monthly) of dabigatran and rivaroxaban use among 29977 hemodialysis patients with atrial fibrillation." | 7.81 | Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. ( Chan, KE; Edelman, ER; Maddux, FW; Thadhani, RI; Wenger, JB, 2015) |
"Bleeding and thromboembolic events during the periprocedural period were evaluated in 363 consecutive patients who underwent CA for AF at Nagoya University Hospital, and received uninterrupted dabigatran (n=173) or uninterrupted warfarin (n=190) for periprocedural anticoagulation." | 7.81 | Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation. ( Fujita, M; Hirai, M; Inden, Y; Ishikawa, S; Kato, H; Miyoshi, A; Murohara, T; Nagao, T; Ohguchi, S; Okumura, S; Shimano, M; Yamamoto, T; Yanagisawa, S; Yoshida, N, 2015) |
" Less bleeding but more acute coronary events with dabigatran, and still no antidote." | 7.81 | Dabigatran (Pradaxa): deep vein thrombosis and pulmonary embolism. Warfarin remains the standard drug. ( , 2015) |
"Excessive anticoagulation with warfarin can result in acute kidney injury (AKI) by causing glomerular hemorrhage and renal tubular obstruction by red blood cell (RBC) casts in some patients, especially in those with chronic kidney disease (CKD)." | 7.80 | Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats. ( Brodsky, SV; Hebert, L; Nadasdy, G; Nadasdy, T; Qamri, Z; Rovin, B; Ryan, M; Satoskar, A; Ware, K; Wu, H, 2014) |
"Advantages of dabigatran, a thrombin inhibitor, for stroke prevention in patients with atrial fibrillation are numerous." | 7.80 | Impaired renal function and bleeding in elderly treated with dabigatran. ( Assayag, P; Berthelot, E; Desconclois, C; Lavenu-Bombled, C; Orostegui-Giron, L, 2014) |
"By using nationwide Danish prescription and patient registries, we identified 11,315 first-time dabigatran users with atrial fibrillation." | 7.80 | Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. ( Gorst-Rasmussen, A; Larsen, TB; Lip, GY; Rasmussen, LH; Rosenzweig, M; Skjøth, F, 2014) |
"Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban trial only recently reported." | 7.80 | Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. ( Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2014) |
"Evaluate dabigatran adverse event reports with a reported bleeding event and/or reported fatal outcome compared with warfarin." | 7.80 | Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval. ( Bress, A; McConeghy, KW; Nutescu, EA; Qato, DM; Wing, C, 2014) |
"Clinical trial data suggest that dabigatran and warfarin have similar rates of major bleeding but higher rates of gastrointestinal bleeding." | 7.80 | Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. ( Chrischilles, E; Cram, P; Jones, M; Mazur, A; Vaughan Sarrazin, MS, 2014) |
" Indication for dabigatran etexilate was ischemic stroke in 101 patients and acute cerebral hemorrhage (CH) due to warfarin in 5 (4." | 7.80 | Dabigatran in secondary stroke prevention: clinical experience with 106 patients. ( Alonso Cánovas, A; Cruz, A; DeFelipe-Mimbrera, A; Guillán, M; Masjuan, J; Matute, C; Sainz de la Maza, S; Vera, R, 2014) |
" The purpose of this study was to estimate the change in medical costs related to stroke and major bleeding for each NOAC (apixaban, dabigatran, and rivoraxaban) relative to warfarin in a RW NVAF population." | 7.80 | Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population. ( Amin, A; Lawrence, JH; Makenbaeva, D; Stokes, M; Wiederkehr, D; Wu, N, 2014) |
" New oral anticoagulants (apixaban, rivaroxaban and dabigatran) are recommended for antithrombotic therapy in patients with non-valvular atrial fibrillation (NVAF) with moderate and high risk of stroke." | 7.80 | [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation]. ( Rudakova, AV; Tatarskiĭ, BA, 2014) |
"Bleeding complications post-ablation were similar for warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation." | 7.80 | A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation. ( Duart, M; Kauffman, C; Kusumoto, F; Ray, JC; Snipelisky, D; Ung, R, 2014) |
"We report a case of a patient receiving dabigatran who developed a life-threatening bleeding complication during cardiac ablation that rapidly resolved after administration of Factor Eight Inhibitor Bypassing Activity (FEIBA)." | 7.79 | Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. ( Dager, WE; Gosselin, RC; Roberts, AJ, 2013) |
"It is a case report of bleeding when using dabigatran in patient with renal failure caused by the concurrent use of spironolactone and angiotensin-converting enzyme (ACE) inhibitors." | 7.79 | [Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors]. ( Andreev, DA; Gappoeva, ZK; Giliarov, MIu; Sychev, DA, 2013) |
"Alternative anticoagulants to warfarin (dabigatran, rivaroxaban, and apixaban) are becoming available for the prevention of thromboembolic stroke in atrial fibrillation (AF), but there is a lack of information on their comparative effectiveness." | 7.79 | Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. ( Hughes, DA; Pink, J; Pirmohamed, M, 2013) |
" We evaluated the influence of the putative etiological variables and the bleeding score, HAS-BLED score, on APTT values: age greater than 70 years, renal function, gender, dose of dabigatran, and the concomitant prescription of a P-glycoprotein inhibitor." | 7.79 | Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice. ( Hachiya, H; Hirao, K; Isobe, M; Kawabata, M; Nakamura, T; Sasano, T; Sugiyama, K; Suzuki, M; Tanaka, Y; Yagishita, A; Yokoyama, Y, 2013) |
"The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear." | 7.79 | Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013) |
"To identify risk factors which increase the risk of hemorrhage under NOA, we performed a PubMed search for both dabigatran and rivaroxaban, as well as three search terms for hemorrhagic complications." | 7.79 | The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation. ( Brunkhorst, R; Foerch, C; Lindhoff-Last, E; Luger, S; Pfeilschifter, W, 2013) |
"Patients receiving dabigatran were younger and at a lower risk of stroke and bleeding." | 7.79 | Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Holmes, DN; Hylek, EM; Kowey, PR; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013) |
" Six months before presentation, the patient was placed on Dabigatran etexilate (Dabigatran) (110 mg BID) for atrial fibrillation." | 7.79 | The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis. ( Beydoun, A; Husari, A; Maakaron, JE; Sheik Ammar, A; Taher, A, 2013) |
"In patients undergoing AF ablation, periprocedural dabigatran use significantly increases the risk of bleeding or thromboembolic complications compared with uninterrupted warfarin therapy." | 7.78 | Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. ( Burkhardt, JD; Chalhoub, F; Coffey, J; D'Avila, A; Di Biase, L; Lakkireddy, D; Mansour, MC; Mohanty, P; Monir, G; Natale, A; Pimentel, R; Reddy, VY; Reddy, YM; Ruskin, J; Sanchez, JE; Santangeli, P; Shaik, N; Swarup, V; Vanga, SR, 2012) |
"To report clinical challenges in managing dabigatran-induced bleeding." | 7.78 | Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. ( Cano, EL; Miyares, MA, 2012) |
"In our cohort, bleeding-related complications 48 h and 1 week post-ablation were similar for warfarin and dabigatran." | 7.78 | A comparison of bleeding complications post-ablation between warfarin and dabigatran. ( Johns, G; Kauffman, C; Kusumoto, F; Prussak, K; Snipelisky, D; Venkatachalam, K, 2012) |
"Cost considered: the drugs for the prevention of VTE (apixaban, dabigatran, enoxaparin, fondaparinux, other heparins, rivaroxaban and warfarin) and the complications of VTE in the short term and in 5 years (deep vein thrombosis, pulmonary embolism, bleedings and the post-thrombotic syndrome)." | 7.78 | [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement]. ( Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C, 2012) |
"To estimate the quality-adjusted survival, costs, and cost-effectiveness of dabigatran compared with adjusted-dose warfarin for preventing ischemic stroke in patients 65 years or older with nonvalvular AF." | 7.77 | Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. ( Freeman, JV; Garber, AM; Go, AS; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP, 2011) |
"Dabigatran 150 mg (twice daily) was cost-effective in AF populations at high risk of hemorrhage or high risk of stroke unless international normalized ratio control with warfarin was excellent." | 7.77 | Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. ( Gage, BF; Shah, SV, 2011) |
"Clinical results of the European Action on Anticoagulation (EAA) computer-assisted dosage study and the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial have been compared." | 6.79 | Warfarin or dabigatran for treatment of atrial fibrillation. ( Ibrahim, S; Jespersen, J; Poller, L, 2014) |
" Rywaroxaban more frequently causes minor bleeding, whereas treatment with dabigatran is associated with more frequent gastrointestinal adverse symptoms." | 6.79 | [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation]. ( Broncel, M; Ciastkowska, A; Duraj, I; Gorzelak-Pabiś, P; Szlagowska, L, 2014) |
"Dabigatran is a univalent low-molecular-weight direct thrombin inhibitor that has been developed as an alternative to vitamin K antagonists (VKAs)." | 6.50 | Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran. ( Atallah, R; Bloom, BJ; Eisenberg, MJ; Filion, KB, 2014) |
"Dabigatran is an oral anticoagulant that inhibits thrombin but not vitamin K." | 6.49 | Dabigatran: life-threatening bleeding. ( , 2013) |
"Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1." | 6.47 | Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. ( Kwok, CS; Loke, YK, 2011) |
" Additional concerns refer to the dosing-regimens and their practical administration: Fondaparinux, rivaroxaban and dabigatran are dosed to achieve maximum effects very close to their limits of tolerance whereas wide dosing spectra for the low molecular weight herparin (LMWH)'s indicate the potential for dose adaptation and increase." | 6.47 | Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux. ( Fareed, J; Hull, R; Welzel, D, 2011) |
"Dabigatran (Pradaxa) is a competitive direct thrombin inhibitor approved by the US FDA for prevention of embolic stroke in patients with nonvalvular atrial fibrillation." | 6.47 | Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. ( Babu, KM; Boyer, EW; Brown, RS; Ganetsky, M; Salhanick, SD, 2011) |
"Warfarin and aspirin are used to prevent stroke in patients with atrial fibrillation (AF)." | 6.27 | Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. ( Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M, 2013) |
"The aim of this study was to compare the management and prognosis of major bleeding in patients treated with dabigatran or warfarin." | 6.27 | Management and outcomes of major bleeding during treatment with dabigatran or warfarin. ( Brueckmann, M; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Fraessdorf, M; Hwang, HG; Majeed, A; Schulman, S; Wallentin, L; Yusuf, S, 2013) |
" The rate of occurrences of adverse effects and bleeding were lower than those seen in the RE-LY trial." | 5.40 | A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation. ( Hussin, A; Kaur, S; Muhammad, Z; Omar, R; Rusani, BI; Umadevan, D; Yap, LB, 2014) |
"Dabigatran is an oral direct thrombin inhibitor indicated for thromboembolism prophylaxis in patients with nonvalvular atrial fibrillation." | 5.39 | Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose. ( Chen, BC; Dadzie, KA; Hoffman, RS; Nelson, LS; Sheth, NR; Smith, SW; Winchester, JF, 2013) |
"Dabigatran is a new anticoagulant and may be useful after AF ablation to prevent thromboembolic events." | 5.38 | The use of dabigatran immediately after atrial fibrillation ablation. ( Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA, 2012) |
"Dabigatran is a direct thrombin inhibitor, acting like other members in its class (bivalirudin, argatroban) to impede the clotting process through selective and reversible binding with both free and clot-bound thrombin." | 5.38 | Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation. ( Boniface, K; Moore, CH; Scott, J; Snashall, J, 2012) |
"We undertook this prospective cohort study to determine the safety of 5 g of intravenous idarucizumab and its capacity to reverse the anticoagulant effects of dabigatran in patients who had serious bleeding (group A) or required an urgent procedure (group B)." | 5.20 | Idarucizumab for Dabigatran Reversal. ( Bernstein, RA; Dubiel, R; Eikelboom, J; Glund, S; Huisman, MV; Hylek, EM; Kam, CW; Kamphuisen, PW; Kreuzer, J; Levy, JH; Pollack, CV; Reilly, PA; Sellke, FW; Stangier, J; Steiner, T; Verhamme, P; Wang, B; Weitz, JI, 2015) |
"Dabigatran has similar effects on VTE recurrence and a lower risk of bleeding compared with warfarin for the treatment of acute VTE." | 5.19 | Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. ( Christiansen, AV; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Le Maulf, F; Mismetti, P; Peter, N; Schellong, S; Schulman, S, 2014) |
"We observed a rate of major bleeding similar to that reported in randomized clinical trials among patients with AF prescribed dabigatran or rivaroxaban." | 5.19 | Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting. ( Evans, RS; Fontaine, GV; Lloyd, JF; Mathews, KD; Stevens, SM; Woller, SC, 2014) |
"Dabigatran was effective in the extended treatment of venous thromboembolism and carried a lower risk of major or clinically relevant bleeding than warfarin but a higher risk than placebo." | 5.17 | Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. ( Baanstra, D; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Kvamme, AM; Mismetti, P; Schellong, S; Schulman, S, 2013) |
"In 18,113 AF patients in the RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) trial, we used a previously developed method for integrating ischemic and bleeding events as "ischemic stroke equivalents" in order to compare a weighted benefit of 2 doses of dabigatran with each other, and with that of warfarin." | 5.17 | Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. ( Connolly, SJ; Eikelboom, JW; Hart, RG; Oldgren, J; Reilly, P; Wallentin, L; Yang, S; Yusuf, S, 2013) |
"3 years of continued treatment with dabigatran after RE-LY, there was a higher rate of major bleeding with dabigatran 150 mg twice daily in comparison with 110 mg, and similar rates of stroke and death." | 5.17 | The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. ( Alings, M; Amerena, JV; Avezum, A; Baumgartner, I; Brueckmann, M; Budaj, AJ; Chen, JH; Connolly, SJ; Dans, AL; Darius, H; Di Pasquale, G; Duffy, CO; Eikelboom, J; Ezekowitz, MD; Ferreira, J; Flaker, GC; Flather, MD; Franzosi, MG; Golitsyn, SP; Halon, DA; Heidbuchel, H; Hohnloser, SH; Huber, K; Jansky, P; Kamensky, G; Keltai, M; Kim, SS; Lau, CP; Le Heuzey, JY; Lewis, BS; Liu, L; Nanas, J; Oldgren, J; Omar, R; Pais, P; Pedersen, KE; Piegas, LS; Pogue, J; Raev, D; Reilly, PA; Smith, PJ; Talajic, M; Tan, RS; Tanomsup, S; Themeles, E; Toivonen, L; Vinereanu, D; Wallentin, L; Wang, SQ; Xavier, D; Yusuf, S; Zhu, J, 2013) |
"The trial was terminated prematurely after the enrollment of 252 patients because of an excess of thromboembolic and bleeding events among patients in the dabigatran group." | 5.17 | Dabigatran versus warfarin in patients with mechanical heart valves. ( Blatchford, J; Brueckmann, M; Connolly, SJ; Devenny, K; Eikelboom, JW; Friedman, J; Granger, CB; Guiver, K; Harper, R; Kappetein, AP; Khder, Y; Lobmeyer, MT; Maas, H; Mack, MJ; Simoons, ML; Van de Werf, F; Voigt, JU, 2013) |
"The distribution of activated partial thromboplastin time (APTT) in nonvalvular atrial fibrillation (NVAF) patients under dabigatran therapy remains to be clarified." | 5.16 | Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time. ( Aizawa, T; Funada, R; Kirigaya, H; Koike, A; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Sawada, H; Suzuki, S; Uejima, T; Yajima, J; Yamashita, T, 2012) |
"Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required." | 5.16 | Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. ( Avezum, A; Connolly, SJ; Douketis, J; Eikelboom, J; Ezekowitz, M; Healey, JS; Heidbuchel, H; Heidbuchle, H; Oldgren, J; Reilly, P; Themeles, E; Wallentin, L; Yang, S; Yusuf, S, 2012) |
" The frequencies of stroke and major bleeding within 30 days of cardioversion on the 2 doses of dabigatran were low and comparable to those on warfarin with or without transesophageal echocardiography guidance." | 5.15 | Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. ( Aikens, TH; Brugada, J; Chernick, M; Connolly, SJ; Ezekowitz, MD; Flaker, G; Kamensky, G; Nagarakanti, R; Oldgren, J; Parekh, A; Reilly, PA; Yang, S; Yusuf, S, 2011) |
"RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) is an international multicenter study (18,113 patients from 967 centers in 44 countries) that demonstrated the ability of dabigatran to reduce the occurrence of both stroke and hemorrhage in patients who had atrial fibrillation (AF) with high risks of stroke compared with patients who received warfarin." | 5.15 | Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial. ( Connolly, SJ; Ezekowitz, MD; Hori, M; Reilly, PA; Wallentin, L; Yusuf, S, 2011) |
"After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel." | 5.15 | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011) |
"In patients with atrial fibrillation at risk for stroke, both doses of dabigatran compared with warfarin have lower risks of both intracranial and extracranial bleeding in patients aged <75 years." | 5.15 | Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. ( Alings, M; Connolly, SJ; Diener, HC; Eikelboom, JW; Ezekowitz, M; Franzosi, MG; Healey, JS; Hohnloser, SH; Huber, K; Kaatz, S; Oldgren, J; Reilly, P; Varrone, J; Wallentin, L; Yang, S; Yusuf, S, 2011) |
"To evaluate the prognostic importance of CHADS(2) risk score in patients with atrial fibrillation receiving oral anticoagulants, including the vitamin K antagonist warfarin and the direct thrombin inhibitor dabigatran." | 5.15 | Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. ( Alings, M; Connolly, SJ; Darius, H; Diener, HC; Eikelboom, J; Ezekowitz, MD; Kamensky, G; Oldgren, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S, 2011) |
"In patients undergoing hip or knee arthroplasty, enoxaparin and dabigatran showed similar rates of efficacy and bleeding." | 5.14 | Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. ( Dahl, OE; Huisman, MV; Quinlan, DJ; Schulman, S, 2010) |
"In October 2011, DTB reviewed the use of dabigatran, the first new oral anticoagulant licensed for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) and one or more defined risk factors." | 4.90 | {blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF. ( , 2014) |
" In Thrombin Receptor Antagonists for Clinical Event Reduction (TRA-CER), compared with standard care alone, bleeding complications including intracranial hemorrhage (ICH) were increased with the addition of vorapaxar, without efficacy benefit." | 4.90 | New antithrombotics for secondary prevention of acute coronary syndrome. ( Goto, S; Tomita, A, 2014) |
"During the past four years the phase III trials on stroke prophylaxis in atrial fibrillation and on treatment of venous thromboembolism have been completed for four new oral anticoagulants - dabigatran, apixaban, edoxaban and rivaroxaban." | 4.90 | New oral anticoagulant agents - general features and outcomes in subsets of patients. ( Schulman, S, 2014) |
"Since the approval of dabigatran etexilate, numerous case reports have suggested the potential dangers of bleeding complications, especially given that there is no known antidote." | 4.90 | Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population. ( Brunetti, L; Chen, C; White, J, 2014) |
" In the second part of the review is discussed higher incidence of myocardial infarction in controlled group in the trial comparing treatment of dabigatran with warfarin." | 4.90 | [Anticoagulant therapy in secondary prevention of coronary events]. ( Bultas, J, 2014) |
" If bleeding occurs in patients who have received these agents, common principles of bleeding management as with any anticoagulant (including the known principles for warfarin) should be considered." | 4.89 | Managing new oral anticoagulants in the perioperative and intensive care unit setting. ( Douketis, JD; Faraoni, D; Levy, JH; Samama, CM; Spring, JL, 2013) |
" This review discusses current anticoagulation reversal recommendations for the oral anticoagulants warfarin, dabigatran, and rivaroxaban for patients at a heightened risk of bleeding, actively bleeding, or those in need of preprocedural anticoagulation reversal." | 4.89 | Reversal of oral anticoagulation. ( Limdi, NA; Thigpen, JL, 2013) |
"Dabigatran was the first of a new generation of anticoagulation drugs for the indication of non-valvular atrial fibrillation (AF) to be approved." | 4.89 | Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide. ( Asmussen, MB; Hesselbjerg, LJ; Pedersen, HS; Petersen, KD, 2013) |
"Dabigatran is an oral, direct, and competitive inhibitor of thrombin, which is administered to patients with non-valvular atrial fibrillation for prevention of stroke at a dose of 110 mg twice daily or 150 mg twice daily." | 4.89 | [Direct oral thrombin inhibitor, "dabigatran"]. ( Yasaka, M, 2013) |
"This article will provide a brief introduction to these new oral anticoagulants and then review the approaches that can be taken for the emergency management of hemostasis in patients bleeding or at risk for bleeding while receiving warfarin or one of two newer agents, the direct thrombin inhibitor dabigatran or the factor Xa inhibitor rivaroxaban." | 4.89 | Managing bleeding in anticoagulated patients in the emergency care setting. ( Pollack, CV, 2013) |
"The primary objective was to assess the cost-effectiveness of new oral anticoagulants compared with warfarin in patients with nonvalvular atrial fibrillation." | 4.89 | Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. ( Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA, 2013) |
"To summarise and compare the efficacy and safety of various oral anticoagulants (dabigatran, rivaroxaban, apixaban, and vitamin K antagonists) and antiplatelet agents (acetylsalicylic acid) for the secondary prevention of venous thromboembolism." | 4.89 | Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. ( Cameron, C; Carrier, M; Castellucci, LA; Clifford, T; Coyle, D; Gandara, E; Le Gal, G; Rodger, MA; Wells, G; Wells, PS, 2013) |
" Dabigatran: elderly patients with renal failure are at higher risk of bleeding." | 4.89 | [Pharmacovigilance update]. ( Livio, F, 2013) |
"Dabigatran and rivaroxaban are novel anticoagulants that have been approved for the prevention of thromboembolic events in atrial fibrillation." | 4.89 | Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians. ( Brem, E; Foran, M; Koyfman, A, 2013) |
" Clinicians need to be aware of some of the drawbacks associated with the use of dabigatran and, in particular, its reduced clearance in the setting of renal failure and the lack of an effective reversing agent when bleeding does occur." | 4.89 | Thrombin inhibitors: surgical considerations and pharmacology. ( Breik, O; Devitt, P; Tadros, R, 2013) |
"Dabigatran is a direct inhibitor of thrombin that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation." | 4.88 | Preventing cardioembolic stroke in atrial fibrillation with dabigatran. ( Diener, HC; Eikelboom, JW; Hohnloser, SH; Weimar, C, 2012) |
"Warfarin has long been considered the gold standard for stroke prevention in patients with atrial fibrillation (AF)." | 4.88 | ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation? ( Parma, Z; Syzdół, M; Tendera, M, 2012) |
"The present systematic review was conducted to assess the efficacy and safety of apixaban versus other anticoagulants, for the prevention of venous thromboembolism (VTE) following total hip replacement (THR) and total knee replacement (TKR) surgery." | 4.88 | The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis. ( Cohen, A; Drost, P; Marchant, N; Mitchell, S; Orme, M; Rublee, D; Simon, TA; Sutton, A, 2012) |
"For patients with atrial fibrillation and a high risk of thrombosis, the standard prophylaxis is warfarin, an anticoagulant, at a dose adjusted to the INR." | 4.88 | Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients. ( , 2012) |
" New platelet inhibitors prasugrel and ticagrelor are more effective than the traditional clopidogrel, but their use is also accompanied by more frequent bleeding complications." | 4.88 | [New antithrombotic drugs]. ( Mustonen, P; Puurunen, M, 2012) |
"New oral anticoagulant drugs are emerging as alternatives to warfarin for the prevention of stroke in patients with non-valvular atrial fibrillation." | 4.88 | An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. ( Ansell, J; Mantha, S, 2012) |
"In this overview we address the three phase III studies that compared new oral anticoagulants (dabigatran, rivaroxaban and apixaban) with warfarin in the setting of stroke prevention in atrial fibrillation." | 4.88 | Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. ( Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Moia, M; Palareti, G; Pengo, V; Poli, D; Siragusa, S; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A, 2012) |
" Dabigatran, does not require dose-adjustment and appears to be more effective at reducing the risk of stroke with similar risks of bleeding in patients with atrial fibrillation (AF)." | 4.88 | Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison. ( Alonso-Coello, P; Guyatt, G; Zhou, Q, 2012) |
" The factor Xa inhibitor, rivaroxaban, has shown promising results in the treatment of acute coronary syndrome but is not yet approved for that indication." | 4.88 | What did we learn from new oral anticoagulant treatment? ( Esmon, CT, 2012) |
"We present data on possibility of anticoagulant therapy in conjunction with electrical cardioversion in patients with atrial fibrillation using novel anticoagulant - dabigatran - and a case of successful lysis of thrombus in the left ventricular cavity at the background of its administration." | 4.88 | [Anticoagulant therapy in connection with cardioversion in patients with atrial fibrillation]. ( Dovgalevskiĭ, IaP; Furman, NV; Kuvshinova, LE, 2012) |
"In patients with NVAF at risk of stroke, the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial demonstrated that, compared with warfarin, dabigatran 150 mg b." | 4.88 | New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran. ( Barrios, V; Escobar, C, 2012) |
"Dabigatran and other new oral anticoagulants (OAC) represent a step forward in stroke prevention in patients with atrial fibrillation (AF)." | 4.87 | Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). ( Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Palareti, G; Pengo, V; Poli, D; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A, 2011) |
"The comparative safety of dabigatran versus warfarin for treatment of nonvalvular atrial fibrillation in general practice settings has not been established." | 3.81 | Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. ( Goulding, MR; Graham, DJ; Houstoun, M; Kelman, JA; Levenson, M; MaCurdy, TE; Mott, K; Reichman, ME; Sheu, TC; Southworth, MR; Wernecke, M; Worrall, C; Zhang, R, 2015) |
"It remains unclear whether dabigatran etexilate mesylate is associated with higher risk of bleeding than warfarin sodium in real-world clinical practice." | 3.81 | Risk of bleeding with dabigatran in atrial fibrillation. ( Baik, SH; Hernandez, I; Piñera, A; Zhang, Y, 2015) |
"Although dabigatran, an oral direct thrombin inhibitor, does not require routine monitoring, high plasma concentration of dabigatran (PDC) at trough level is shown to be a high risk for bleeding in patients with nonvalvular atrial fibrillation (NVAF)." | 3.81 | CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough. ( Horiuchi, D; Ishida, Y; Itoh, T; Kimura, M; Kinjo, T; Okumura, K; Owada, S; Sasaki, K; Sasaki, S; Tomita, H, 2015) |
"Compared with warfarin, periprocedural anticoagulation with dabigatran resulted in fewer minor hemorrhages and total adverse events after AF ablation." | 3.81 | Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. ( Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD, 2015) |
"Prevalence plots were used to describe the point prevalence (monthly) of dabigatran and rivaroxaban use among 29977 hemodialysis patients with atrial fibrillation." | 3.81 | Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. ( Chan, KE; Edelman, ER; Maddux, FW; Thadhani, RI; Wenger, JB, 2015) |
"A report has demonstrated that in patients with atrial fibrillation the novel oral anticoagulant, dabigatran, increases the risk of gastrointestinal bleeding by nearly twofold compared with warfarin." | 3.81 | Gastrointestinal bleeding. Gastrointestinal bleeding risk is increased by novel anticoagulants. ( Rockey, DC, 2015) |
"Severe bleeding associated with dabigatran frequently requires intensive care management." | 3.81 | Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. ( Bernier-Jean, A; Bouchard, J; Eris, JM; Ghannoum, M; Kershaw, G; Patel, JP; Roberts, DM; Tran, H; Weatherburn, C; Williamson, D, 2015) |
"The objectives of this national chart audit (January to June 2013) of 6,346 patients with atrial fibrillation (AF; ≥18 years without a significant heart valve disorder) from 647 primary care physicians were to (1) describe the frequency of stroke and bleed risk assessments in patients with nonvalvular AF by primary care physicians, including the accuracy of these assessments relative to established predictive indexes; (2) outline contemporary methods of anticoagulation used; and (3) report the time in the therapeutic range among patients prescribed warfarin." | 3.81 | Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit). ( Angaran, P; Bell, AD; Berall, M; Bucci, C; Demchuk, AM; Essebag, V; Goldin, L; Goodman, SG; Green, MS; Gregoire, JC; Gross, PL; Heilbron, B; Lin, PJ; Patel, AD; Ramanathan, K; Skanes, A; Tan, MK; Wheeler, BH, 2015) |
"Bleeding and thromboembolic events during the periprocedural period were evaluated in 363 consecutive patients who underwent CA for AF at Nagoya University Hospital, and received uninterrupted dabigatran (n=173) or uninterrupted warfarin (n=190) for periprocedural anticoagulation." | 3.81 | Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation. ( Fujita, M; Hirai, M; Inden, Y; Ishikawa, S; Kato, H; Miyoshi, A; Murohara, T; Nagao, T; Ohguchi, S; Okumura, S; Shimano, M; Yamamoto, T; Yanagisawa, S; Yoshida, N, 2015) |
"Twenty-seven patients taking dabigatran underwent 41 cutaneous surgeries, with only 1 mild bleeding complication observed that was remedied with a pressure dressing." | 3.81 | Complications With New Oral Anticoagulants Dabigatran and Rivaroxaban in Cutaneous Surgery. ( Arpey, CJ; Baum, CL; Brewer, JD; Chang, TW; Hochwalt, PC; Hocker, TL; Otley, CC; Roenigk, RK, 2015) |
" Less bleeding but more acute coronary events with dabigatran, and still no antidote." | 3.81 | Dabigatran (Pradaxa): deep vein thrombosis and pulmonary embolism. Warfarin remains the standard drug. ( , 2015) |
"Excessive anticoagulation with warfarin can result in acute kidney injury (AKI) by causing glomerular hemorrhage and renal tubular obstruction by red blood cell (RBC) casts in some patients, especially in those with chronic kidney disease (CKD)." | 3.80 | Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats. ( Brodsky, SV; Hebert, L; Nadasdy, G; Nadasdy, T; Qamri, Z; Rovin, B; Ryan, M; Satoskar, A; Ware, K; Wu, H, 2014) |
"In the RE-LY trial dabigatran 150 mg twice daily (D150) showed significantly fewer strokes, and 110 mg (D110) significantly fewer major bleeding events (MBE) compared to well-controlled warfarin in patients with atrial fibrillation (AF)." | 3.80 | Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. ( Clemens, A; Connolly, SJ; Ferreira, J; Lip, GY; Noack, H; Yusuf, S, 2014) |
"Dabigatran is a direct thrombin inhibitor indicated for stroke and systemic embolism prevention in patients with non-valvular atrial fibrillation." | 3.80 | [Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery]. ( Bachellerie, B; Conil, JM; Crognier, L; Fourcade, O; Georges, B; Ruiz, S; Seguin, T, 2014) |
" Therefore, we compared the incidence of bleeding and thrombo-embolic complications following cardiac rhythm device (CRD) implantations under dabigatran vs." | 3.80 | Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations. ( Bollmann, A; Breithardt, OA; Dinov, B; Doering, M; Hindricks, G; Kosiuk, J; Koutalas, E; Nedios, S; Richter, S; Rolf, S; Sommer, P, 2014) |
"Advantages of dabigatran, a thrombin inhibitor, for stroke prevention in patients with atrial fibrillation are numerous." | 3.80 | Impaired renal function and bleeding in elderly treated with dabigatran. ( Assayag, P; Berthelot, E; Desconclois, C; Lavenu-Bombled, C; Orostegui-Giron, L, 2014) |
"By using nationwide Danish prescription and patient registries, we identified 11,315 first-time dabigatran users with atrial fibrillation." | 3.80 | Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. ( Gorst-Rasmussen, A; Larsen, TB; Lip, GY; Rasmussen, LH; Rosenzweig, M; Skjøth, F, 2014) |
" We determined intracerebral hemorrhage volume and functional outcome in a standardized TBI model in mice treated with warfarin or dabigatran." | 3.80 | Translational insights into traumatic brain injury occurring during dabigatran or warfarin anticoagulation. ( Foerch, C; Lauer, A; Leung, W; Lo, EH; Lok, J; Schaefer, JH; Van Cott, EM; van Leyen, K; van Ryn, J; Whalen, M; Wu, L, 2014) |
"Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban trial only recently reported." | 3.80 | Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. ( Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2014) |
"Evaluate dabigatran adverse event reports with a reported bleeding event and/or reported fatal outcome compared with warfarin." | 3.80 | Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval. ( Bress, A; McConeghy, KW; Nutescu, EA; Qato, DM; Wing, C, 2014) |
"New oral anticoagulants (NOACs) offer an alternative to warfarin for preventing stroke in patients with atrial fibrillation." | 3.80 | Perioperative management of patients on new oral anticoagulants. ( Davidson, N; Galloway, SW; Lai, A; Thachil, J, 2014) |
" Adherence to dabigatran was not associated with non-fatal bleeding or myocardial infarction." | 3.80 | Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. ( Barón, AE; Bradley, SM; Carey, EP; Cunningham, F; Grunwald, GK; Ho, PM; Jackevicius, CA; Maddox, TM; Marzec, LN; Pilote, L; Rumsfeld, JS; Schneider, PM; Shore, S; Turakhia, MP; Varosy, PD, 2014) |
"This study evaluated differences in medical costs associated with clinical end-points from randomized clinical trials that compared the new oral anticoagulants (NOACs), dabigatran, rivaroxaban, apixaban, and edoxaban, to standard therapy for treatment of patients with venous thromboembolism (VTE)." | 3.80 | Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients. ( Amin, A; Graham, J; Jing, Y; Lin, J; Lingohr-Smith, M; Trocio, J, 2014) |
"Dabigatran, an oral direct thrombin inhibitor, possesses several advantages over warfarin that can in principle simplify the management of stroke prevention in atrial fibrillation (AF)." | 3.80 | Continuation of dabigatran therapy in "real-world" practice in Hong Kong. ( Chan, EW; Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Leung, GK; Siu, CW; Tse, HF, 2014) |
"Clinical trial data suggest that dabigatran and warfarin have similar rates of major bleeding but higher rates of gastrointestinal bleeding." | 3.80 | Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. ( Chrischilles, E; Cram, P; Jones, M; Mazur, A; Vaughan Sarrazin, MS, 2014) |
" Indication for dabigatran etexilate was ischemic stroke in 101 patients and acute cerebral hemorrhage (CH) due to warfarin in 5 (4." | 3.80 | Dabigatran in secondary stroke prevention: clinical experience with 106 patients. ( Alonso Cánovas, A; Cruz, A; DeFelipe-Mimbrera, A; Guillán, M; Masjuan, J; Matute, C; Sainz de la Maza, S; Vera, R, 2014) |
" The purpose of this study was to estimate the change in medical costs related to stroke and major bleeding for each NOAC (apixaban, dabigatran, and rivoraxaban) relative to warfarin in a RW NVAF population." | 3.80 | Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population. ( Amin, A; Lawrence, JH; Makenbaeva, D; Stokes, M; Wiederkehr, D; Wu, N, 2014) |
"Dabigatran, a direct thrombin inhibitor, is licensed for the prevention of venous thromboembolism after knee and hip replacement, the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and for the treatment of acute venous thromboembolism." | 3.80 | Dabigatran: patient management in specific clinical settings. ( Binder, K; Domanovits, H; Eichinger, S; Függer, R; Gollackner, B; Hiesmayr, JM; Huber, K; Kyrle, PA; Lang, W; Perger, P; Quehenberger, P; Roithinger, FX; Schmaldienst, S; Weltermann, A, 2014) |
" New oral anticoagulants (apixaban, rivaroxaban and dabigatran) are recommended for antithrombotic therapy in patients with non-valvular atrial fibrillation (NVAF) with moderate and high risk of stroke." | 3.80 | [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation]. ( Rudakova, AV; Tatarskiĭ, BA, 2014) |
" Dabigatran has emerged as a promising alternative to vitamin K antagonists (VKAs) in non-valvular atrial fibrillation (NVAF)." | 3.80 | [Eligibility for dabigatran therapy: the real-life experience of a Tuscany general hospital]. ( Banfi, R; Fallani, F; Palazzi, N; Pugi, A, 2014) |
"Bleeding complications post-ablation were similar for warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation." | 3.80 | A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation. ( Duart, M; Kauffman, C; Kusumoto, F; Ray, JC; Snipelisky, D; Ung, R, 2014) |
" A direct thrombin inhibitor, dabigatran etexilate (hereinafter referred to as dabigatran) was approved in the Russian Federation for prevention of thromboembolic complications in orthopaedic practice (2009), for prevention of ischaemic embologenic stroke in atrial fibrillation (2011) and for treatment of recurrent thrombosis of deep veins and pulmonary artery thromboembolism (2014)." | 3.80 | [Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor]. ( Beliavskaia, OO; Vavilova, TV, 2014) |
"We report a case of a patient receiving dabigatran who developed a life-threatening bleeding complication during cardiac ablation that rapidly resolved after administration of Factor Eight Inhibitor Bypassing Activity (FEIBA)." | 3.79 | Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. ( Dager, WE; Gosselin, RC; Roberts, AJ, 2013) |
"This was a prospective observational study of ED patients under treatment with dabigatran or warfarin who were admitted with bleeding complications during a 6-month period." | 3.79 | Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin. ( Berger, R; Chase, M; Ganetsky, M; Salhanick, SD, 2013) |
"It is a case report of bleeding when using dabigatran in patient with renal failure caused by the concurrent use of spironolactone and angiotensin-converting enzyme (ACE) inhibitors." | 3.79 | [Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors]. ( Andreev, DA; Gappoeva, ZK; Giliarov, MIu; Sychev, DA, 2013) |
"Alternative anticoagulants to warfarin (dabigatran, rivaroxaban, and apixaban) are becoming available for the prevention of thromboembolic stroke in atrial fibrillation (AF), but there is a lack of information on their comparative effectiveness." | 3.79 | Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. ( Hughes, DA; Pink, J; Pirmohamed, M, 2013) |
"To reverse the anticoagulant effects of warfarin in patients who are bleeding or need surgery, exogenous vitamin K (phytonadione) may be used in combination with another, shorter-acting intervention, such as fresh frozen plasma (FFP), prothrombin complex concentrate (PCC), recombinant factor VIIa, or activated PCC (aPCC)." | 3.79 | Pharmacologic interventions for reversing the effects of oral anticoagulants. ( Kalus, JS, 2013) |
" We evaluated the influence of the putative etiological variables and the bleeding score, HAS-BLED score, on APTT values: age greater than 70 years, renal function, gender, dose of dabigatran, and the concomitant prescription of a P-glycoprotein inhibitor." | 3.79 | Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice. ( Hachiya, H; Hirao, K; Isobe, M; Kawabata, M; Nakamura, T; Sasano, T; Sugiyama, K; Suzuki, M; Tanaka, Y; Yagishita, A; Yokoyama, Y, 2013) |
"The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear." | 3.79 | Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013) |
"To determine the risk of bleeding and thromboembolic complications associated with uninterrupted OAC during CIED implantation, replacement, or revision, the outcomes of patients receiving uninterrupted dabigatran (D) were compared to those receiving warfarin (W)." | 3.79 | Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin. ( Doppalapudi, H; Gunter, A; Jennings, JM; Kay, GN; McElderry, HT; Osorio, J; Plumb, VJ; Robichaux, R; Yamada, T, 2013) |
"To identify risk factors which increase the risk of hemorrhage under NOA, we performed a PubMed search for both dabigatran and rivaroxaban, as well as three search terms for hemorrhagic complications." | 3.79 | The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation. ( Brunkhorst, R; Foerch, C; Lindhoff-Last, E; Luger, S; Pfeilschifter, W, 2013) |
"The anticoagulant dabigatran has no reversal agent and may cause life-threatening bleeding in patients with trauma or closed-space hemorrhage." | 3.79 | Intravenous lipid emulsion does not reverse dabigatran-induced anticoagulation in a rat model. ( Blum, J; Carreiro, S; Hack, JB, 2013) |
"Patients receiving dabigatran were younger and at a lower risk of stroke and bleeding." | 3.79 | Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Holmes, DN; Hylek, EM; Kowey, PR; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013) |
" Six months before presentation, the patient was placed on Dabigatran etexilate (Dabigatran) (110 mg BID) for atrial fibrillation." | 3.79 | The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis. ( Beydoun, A; Husari, A; Maakaron, JE; Sheik Ammar, A; Taher, A, 2013) |
"In patients undergoing AF ablation, periprocedural dabigatran use significantly increases the risk of bleeding or thromboembolic complications compared with uninterrupted warfarin therapy." | 3.78 | Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. ( Burkhardt, JD; Chalhoub, F; Coffey, J; D'Avila, A; Di Biase, L; Lakkireddy, D; Mansour, MC; Mohanty, P; Monir, G; Natale, A; Pimentel, R; Reddy, VY; Reddy, YM; Ruskin, J; Sanchez, JE; Santangeli, P; Shaik, N; Swarup, V; Vanga, SR, 2012) |
"For patients with nonrheumatic AF, including those with paroxysmal AF, who are (1) at low risk of stroke (eg, CHADS(2) [congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack] score of 0), we suggest no therapy rather than antithrombotic therapy, and for patients choosing antithrombotic therapy, we suggest aspirin rather than oral anticoagulation or combination therapy with aspirin and clopidogrel; (2) at intermediate risk of stroke (eg, CHADS(2) score of 1), we recommend oral anticoagulation rather than no therapy, and we suggest oral anticoagulation rather than aspirin or combination therapy with aspirin and clopidogrel; and (3) at high risk of stroke (eg, CHADS(2) score of ≥ 2), we recommend oral anticoagulation rather than no therapy, aspirin, or combination therapy with aspirin and clopidogrel." | 3.78 | Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. ( Eckman, MH; Fang, MC; Go, AS; Halperin, JL; Howard, PA; Hughes, M; Hylek, EM; Lane, DA; Lip, GYH; Manning, WJ; Schulman, S; Singer, DE; Spencer, FA; You, JJ, 2012) |
"To report clinical challenges in managing dabigatran-induced bleeding." | 3.78 | Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. ( Cano, EL; Miyares, MA, 2012) |
"Dabigatran, an oral thrombin inhibitor, and rivaroxaban and apixaban, oral factor Xa inhibitors, have been found to be safe and effective in reducing stroke risk in patients with atrial fibrillation." | 3.78 | Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. ( Avorn, J; Choudhry, NK; Gagne, JJ; Patrick, AR; Schneeweiss, S, 2012) |
"We compared efficacy and safety of warfarin, direct thrombin inhibitor dabigatran and clopidogrel in prevention of stroke in 210 patients with nonvalvular atrial fibrillation (AF) aged 65-80 years." | 3.78 | [Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation]. ( Kanorskiĭ, SG; Shevelev, VI, 2012) |
"In our cohort, bleeding-related complications 48 h and 1 week post-ablation were similar for warfarin and dabigatran." | 3.78 | A comparison of bleeding complications post-ablation between warfarin and dabigatran. ( Johns, G; Kauffman, C; Kusumoto, F; Prussak, K; Snipelisky, D; Venkatachalam, K, 2012) |
"We present four cases of dabigatran-related bleeding." | 3.78 | Hemorrhagic complications associated with dabigatran use. ( Basciano, P; Chen, BC; Garlich, FM; Hoffman, RS; Howland, MA; Nelson, LS; Smith, SW; Viny, AD, 2012) |
"We compared the efficacy and safety of warfarin, dabigartan, and clopidogrel used to prevent tromboembolism in 210 elderly patients with non-valvular atrial fibrillation depending on the age." | 3.78 | [Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation]. ( Kanorsky, SG; Shevelev, VI, 2012) |
"Cost considered: the drugs for the prevention of VTE (apixaban, dabigatran, enoxaparin, fondaparinux, other heparins, rivaroxaban and warfarin) and the complications of VTE in the short term and in 5 years (deep vein thrombosis, pulmonary embolism, bleedings and the post-thrombotic syndrome)." | 3.78 | [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement]. ( Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C, 2012) |
"To estimate the quality-adjusted survival, costs, and cost-effectiveness of dabigatran compared with adjusted-dose warfarin for preventing ischemic stroke in patients 65 years or older with nonvalvular AF." | 3.77 | Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. ( Freeman, JV; Garber, AM; Go, AS; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP, 2011) |
"Dabigatran 150 mg (twice daily) was cost-effective in AF populations at high risk of hemorrhage or high risk of stroke unless international normalized ratio control with warfarin was excellent." | 3.77 | Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. ( Gage, BF; Shah, SV, 2011) |
"Clinical results of the European Action on Anticoagulation (EAA) computer-assisted dosage study and the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial have been compared." | 2.79 | Warfarin or dabigatran for treatment of atrial fibrillation. ( Ibrahim, S; Jespersen, J; Poller, L, 2014) |
" Rywaroxaban more frequently causes minor bleeding, whereas treatment with dabigatran is associated with more frequent gastrointestinal adverse symptoms." | 2.79 | [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation]. ( Broncel, M; Ciastkowska, A; Duraj, I; Gorzelak-Pabiś, P; Szlagowska, L, 2014) |
"These trials enrolled 5167 people with cancer and VTE." | 2.58 | Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. ( Akl, EA; Barba, M; Hakoum, MB; Kahale, LA; Matar, CF; Schünemann, H; Sperati, F; Terrenato, I; Tsolakian, IG; Yosuico, VE, 2018) |
"Dabigatran is an oral direct thrombin inhibitor (DTI) licensed for stroke prevention in atrial fibrillation and likely to be soon approved in Europe for treatment of venous thrombosis." | 2.50 | The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. ( Alikhan, R; Baglin, T; Benson, G; Green, L; Keeling, D; Marshall, S; Patel, R; Pavord, S; Rayment, R; Rose, P; Tait, C, 2014) |
"Dabigatran is a univalent low-molecular-weight direct thrombin inhibitor that has been developed as an alternative to vitamin K antagonists (VKAs)." | 2.50 | Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran. ( Atallah, R; Bloom, BJ; Eisenberg, MJ; Filion, KB, 2014) |
" They are at least as effective and as safe as conventional therapy (heparins and vitamin-K inhibitors) and have practical advantages, such as fixed dosing and no need for laboratory monitoring." | 2.50 | Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism. ( Bounameaux, H; Fontana, P; Goldhaber, SZ, 2014) |
"Warfarin and heparins have been the predominant anticoagulants used until the past decade." | 2.50 | The newer direct oral anticoagulants: a practical guide. ( Thachil, J, 2014) |
"Dabigatran is a direct thrombin (factor IIa) inhibitor; rivaroxaban and apixaban are direct factor Xa inhibitors." | 2.50 | Newer clinically available antithrombotics and their antidotes. ( Lévy, S, 2014) |
"Ease of dosing and simplicity of monitoring make new oral anticoagulants an attractive therapy in a growing range of clinical conditions." | 2.50 | Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates. ( Baumann Kreuziger, LM; Dries, DJ; Keenan, JC; Morton, CT, 2014) |
"Dabigatran is an oral anticoagulant that inhibits thrombin but not vitamin K." | 2.49 | Dabigatran: life-threatening bleeding. ( , 2013) |
" Consequently, if renal function is impaired, there is a risk of drug accumulation that is highest for dabigatran followed by rivaroxaban and then apixaban and thus dosing recommendations are different." | 2.49 | Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. ( Böhm, M; Dichgans, M; Diener, HC; Ell, C; Endres, M; Epple, C; Grond, M; Laufs, U; Nickenig, G; Riess, H; Röther, J; Schellinger, PD; Spannagl, M; Steiner, T; Veltkamp, R, 2013) |
"Dabigatran is an oral direct thrombin inhibitor widely used to prevent and treat various thromboembolic complications." | 2.49 | Dabigatran and kidney disease: a bad combination. ( Berns, JS; Chaknos, CM; Knauf, F; Perazella, MA, 2013) |
" If the dosage of the drug is not immediately available, proposals only based on the usual tests, PT and aPTT, also are presented." | 2.49 | [Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013]. ( Albaladejo, P; Blais, N; Cohen, A; de Maistre, E; Fontana, P; Godier, A; Gruel, Y; Llau, JV; Mismetti, P; Pernod, G; Rosencher, N; Samama, CM; Samama, MM; Schved, JF; Sié, P; Susen, S, 2013) |
"Risk for symptomatic deep venous thrombosis, but not risk for death or nonfatal pulmonary embolism, was reduced with factor Xa inhibitors compared with LMWH (4 fewer events per 1000 patients)." | 2.49 | Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review. ( Adam, SS; Lachiewicz, PF; McDuffie, JR; Ortel, TL; Williams, JW, 2013) |
"Dabigatran has been introduced into the prevention of stroke in patients with atrial fibrillation." | 2.48 | [Dabigatran and emergency operation on a peritonitis patient]. ( Ilmakunnas, M; Lassila, R; Louhimo, J, 2012) |
" The emergence of new anticoagulants that offer equal or superior efficacy, greater safety and the convenience of fixed oral dosing may make warfarin the less preferred option." | 2.48 | Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. ( Halperin, JL; Varughese, CJ, 2012) |
"Cardioembolic cerebral ischemia can be prevented." | 2.48 | [Prevention of cardioembolic stroke]. ( Gil Núñez, A, 2012) |
" Linearity of dose-response and responsiveness to increasing dose in addition to standardization are other important issues to consider." | 2.48 | Laboratory tests and the new oral anticoagulants. ( Tripodi, A, 2012) |
" Experience with long-term use (> 5 years) is limited." | 2.48 | [Clinical pharmacological aspects of new oral anticoagulants]. ( Haschke, M, 2012) |
"Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1." | 2.47 | Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. ( Kwok, CS; Loke, YK, 2011) |
" Additional concerns refer to the dosing-regimens and their practical administration: Fondaparinux, rivaroxaban and dabigatran are dosed to achieve maximum effects very close to their limits of tolerance whereas wide dosing spectra for the low molecular weight herparin (LMWH)'s indicate the potential for dose adaptation and increase." | 2.47 | Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux. ( Fareed, J; Hull, R; Welzel, D, 2011) |
" Clinicians are increasingly being challenged with making uncertain anticoagulant dosing decisions, as the optimal dosing strategy for most anticoagulants in the obese patient population remains unknown." | 2.47 | Anticoagulating obese patients in the modern era. ( Arya, R; Patel, JP; Roberts, LN, 2011) |
"Dabigatran (Pradaxa) is a competitive direct thrombin inhibitor approved by the US FDA for prevention of embolic stroke in patients with nonvalvular atrial fibrillation." | 2.47 | Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. ( Babu, KM; Boyer, EW; Brown, RS; Ganetsky, M; Salhanick, SD, 2011) |
"Dabigatran is an oral direct thrombin inhibitor with a rapid onset." | 2.47 | Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor. ( Augoustides, JG, 2011) |
"Intracorneal hemorrhages are a rare finding generally associated with surgery or trauma." | 1.72 | Case Report: Intracorneal Hemorrhages Seen with Scleral Contact Lens Wear and Netarsudil Therapy. ( Crum, AR; Srikumaran, D, 2022) |
"Compared to Vitamin K antagonists (VKA), novel oral anticoagulants (NOACs) appear to be safer in terms of major bleeding risks with added advantage of having fixed dosing schedules when used in patients with non-valvular atrial fibrillation (AF)." | 1.42 | Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants. ( Aryal, MR; Badal, M; Chaudhary, A; Donato, AA; Mege, J, 2015) |
" The rate of occurrences of adverse effects and bleeding were lower than those seen in the RE-LY trial." | 1.40 | A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation. ( Hussin, A; Kaur, S; Muhammad, Z; Omar, R; Rusani, BI; Umadevan, D; Yap, LB, 2014) |
"Dabigatran is a novel oral anticoagulant for which a well-defined range of toxicity and proven antidote has not been established." | 1.40 | Evaluation of dabigatran exposures reported to poison control centers. ( Conway, SE; Harrison, DL; Schaeffer, SE, 2014) |
"Dabigatran is a new oral direct thrombin inhibitor." | 1.40 | Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study. ( Engström, M; Johansson, PI; Nilsson, CU; Ostrowski, SR; Sølbeck, S, 2014) |
"Dabigatran is an oral direct thrombin inhibitor indicated for thromboembolism prophylaxis in patients with nonvalvular atrial fibrillation." | 1.39 | Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose. ( Chen, BC; Dadzie, KA; Hoffman, RS; Nelson, LS; Sheth, NR; Smith, SW; Winchester, JF, 2013) |
"Dabigatran is an oral direct thrombin inhibitor that does not require routine laboratory monitoring." | 1.39 | The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. ( Butler, J; Chunilal, S; Hapgood, G; Malan, E; Tran, H, 2013) |
"Dabigatran is a new anticoagulant and may be useful after AF ablation to prevent thromboembolic events." | 1.38 | The use of dabigatran immediately after atrial fibrillation ablation. ( Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA, 2012) |
"Dabigatran is a direct thrombin inhibitor, acting like other members in its class (bivalirudin, argatroban) to impede the clotting process through selective and reversible binding with both free and clot-bound thrombin." | 1.38 | Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation. ( Boniface, K; Moore, CH; Scott, J; Snashall, J, 2012) |
"Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors (DTIs)." | 1.38 | Dabigatran (Pradaxa). ( Comin, J; Kallmes, DF, 2012) |
"Valve thrombus was observed in all study groups." | 1.38 | Dabigatran versus warfarin after mechanical mitral valve replacement in the swine model. ( Bianco, RW; Lahti, MT; Medina, EM; Schomburg, JL, 2012) |
"Neurolathyrism (NL) is a motor neuron disease characterized by spastic paraparesis in the hind legs." | 1.38 | Vascular insult accompanied by overexpressed heme oxygenase-1 as a pathophysiological mechanism in experimental neurolathyrism with hind-leg paraparesis. ( Kawaguchi, K; Kusama-Eguchi, K; Lambein, F, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 298 (99.67) | 24.3611 |
2020's | 1 (0.33) | 2.80 |
Authors | Studies |
---|---|
Crum, AR | 1 |
Srikumaran, D | 1 |
Kahale, LA | 1 |
Hakoum, MB | 1 |
Tsolakian, IG | 1 |
Matar, CF | 1 |
Terrenato, I | 1 |
Sperati, F | 1 |
Barba, M | 1 |
Yosuico, VE | 1 |
Schünemann, H | 1 |
Akl, EA | 1 |
Levy, JH | 3 |
Faraoni, D | 1 |
Spring, JL | 1 |
Douketis, JD | 3 |
Samama, CM | 4 |
Schulman, S | 12 |
Kearon, C | 2 |
Kakkar, AK | 2 |
Schellong, S | 2 |
Eriksson, H | 2 |
Baanstra, D | 1 |
Kvamme, AM | 1 |
Friedman, J | 3 |
Mismetti, P | 3 |
Goldhaber, SZ | 3 |
Alikhan, R | 1 |
Rayment, R | 1 |
Keeling, D | 2 |
Baglin, T | 2 |
Benson, G | 1 |
Green, L | 1 |
Marshall, S | 1 |
Patel, R | 1 |
Pavord, S | 1 |
Rose, P | 1 |
Tait, C | 1 |
Berman, JP | 1 |
Halperin, JL | 4 |
Lenchus, JD | 1 |
Kasmeridis, C | 1 |
Lip, GY | 7 |
Apostolakis, S | 1 |
Dager, WE | 1 |
Gosselin, RC | 1 |
Roberts, AJ | 1 |
Southworth, MR | 2 |
Reichman, ME | 2 |
Unger, EF | 2 |
David, JS | 1 |
Piriou, V | 1 |
Albaladejo, P | 2 |
Hjemdahl, P | 1 |
Johnsson, H | 1 |
Wallén, NH | 1 |
Berger, R | 1 |
Salhanick, SD | 2 |
Chase, M | 1 |
Ganetsky, M | 2 |
Jacobson, BF | 1 |
Louw, S | 1 |
Büller, H | 1 |
Mer, M | 1 |
de Jong, PR | 1 |
Rowji, P | 1 |
Schapkaitz, E | 1 |
Adler, D | 1 |
Beeton, A | 1 |
Hsu, HC | 1 |
Wessels, P | 1 |
Haas, S | 1 |
Lisman, T | 1 |
Kamphuisen, PW | 2 |
Northup, PG | 1 |
Porte, RJ | 1 |
Andreev, DA | 1 |
Gappoeva, ZK | 1 |
Sychev, DA | 1 |
Giliarov, MIu | 1 |
Attia, JR | 1 |
Pearce, R | 1 |
Eikelboom, JW | 10 |
Hankey, GJ | 1 |
Chen, BC | 2 |
Sheth, NR | 1 |
Dadzie, KA | 1 |
Smith, SW | 2 |
Nelson, LS | 2 |
Hoffman, RS | 2 |
Winchester, JF | 1 |
Thigpen, JL | 1 |
Limdi, NA | 1 |
Pink, J | 1 |
Pirmohamed, M | 1 |
Hughes, DA | 1 |
Harris, K | 1 |
Mant, J | 1 |
Hesselbjerg, LJ | 1 |
Pedersen, HS | 1 |
Asmussen, MB | 1 |
Petersen, KD | 1 |
Yasaka, M | 2 |
Nutescu, EA | 2 |
Kalus, JS | 1 |
Healey, JS | 3 |
Eikelboom, J | 6 |
Yang, S | 6 |
Themeles, E | 3 |
Connolly, SJ | 13 |
Yusuf, S | 12 |
Douketis, J | 4 |
Wallentin, L | 11 |
Oldgren, J | 8 |
Heidbuchel, H | 3 |
Avezum, A | 3 |
Reilly, P | 4 |
Ezekowitz, M | 3 |
Ahmad, Y | 1 |
Steiner, T | 3 |
Böhm, M | 1 |
Dichgans, M | 1 |
Diener, HC | 5 |
Ell, C | 1 |
Endres, M | 1 |
Epple, C | 1 |
Grond, M | 1 |
Laufs, U | 1 |
Nickenig, G | 1 |
Riess, H | 1 |
Röther, J | 1 |
Schellinger, PD | 1 |
Spannagl, M | 1 |
Veltkamp, R | 1 |
Kawabata, M | 1 |
Yokoyama, Y | 1 |
Sasano, T | 1 |
Hachiya, H | 1 |
Tanaka, Y | 1 |
Yagishita, A | 1 |
Sugiyama, K | 1 |
Nakamura, T | 1 |
Suzuki, M | 1 |
Isobe, M | 1 |
Hirao, K | 1 |
Van Heukelom, J | 1 |
Lal, Y | 1 |
Sandhu, PS | 1 |
Wilson, C | 1 |
Dalton, E | 1 |
Bogdanov, A | 1 |
Hart, RG | 1 |
Ezekowitz, MD | 8 |
Reilly, PA | 5 |
Brueckmann, M | 4 |
Pogue, J | 1 |
Alings, M | 3 |
Amerena, JV | 1 |
Baumgartner, I | 1 |
Budaj, AJ | 1 |
Chen, JH | 1 |
Dans, AL | 1 |
Darius, H | 2 |
Di Pasquale, G | 1 |
Ferreira, J | 2 |
Flaker, GC | 1 |
Flather, MD | 1 |
Franzosi, MG | 2 |
Golitsyn, SP | 1 |
Halon, DA | 1 |
Hohnloser, SH | 3 |
Huber, K | 3 |
Jansky, P | 1 |
Kamensky, G | 3 |
Keltai, M | 1 |
Kim, SS | 1 |
Lau, CP | 1 |
Le Heuzey, JY | 2 |
Lewis, BS | 1 |
Liu, L | 1 |
Nanas, J | 1 |
Omar, R | 2 |
Pais, P | 1 |
Pedersen, KE | 1 |
Piegas, LS | 1 |
Raev, D | 1 |
Smith, PJ | 1 |
Talajic, M | 1 |
Tan, RS | 1 |
Tanomsup, S | 1 |
Toivonen, L | 1 |
Vinereanu, D | 1 |
Xavier, D | 1 |
Zhu, J | 1 |
Wang, SQ | 1 |
Duffy, CO | 1 |
Hapgood, G | 1 |
Butler, J | 1 |
Malan, E | 1 |
Chunilal, S | 1 |
Tran, H | 3 |
Pollack, CV | 2 |
Coyle, D | 2 |
Coyle, K | 1 |
Cameron, C | 2 |
Lee, K | 1 |
Kelly, S | 1 |
Steiner, S | 1 |
Wells, GA | 1 |
Boos, CJ | 1 |
Nam, M | 1 |
Camm, AJ | 1 |
Stöllberger, C | 1 |
Finsterer, J | 1 |
Lazo-Langner, A | 1 |
Lang, ES | 1 |
Fawole, A | 2 |
Daw, HA | 1 |
Crowther, MA | 3 |
Ferrandis, R | 1 |
Castillo, J | 1 |
de Andrés, J | 1 |
Gomar, C | 1 |
Gómez-Luque, A | 1 |
Hidalgo, F | 1 |
Llau, JV | 2 |
Sierra, P | 1 |
Torres, LM | 1 |
Shortt, B | 1 |
Robinson, M | 1 |
Steinberg, BA | 3 |
Kim, S | 1 |
Piccini, JP | 3 |
Fonarow, GC | 2 |
Lopes, RD | 1 |
Thomas, L | 2 |
Ansell, J | 3 |
Kowey, P | 1 |
Singer, DE | 3 |
Gersh, B | 2 |
Mahaffey, KW | 2 |
Hylek, E | 1 |
Go, AS | 3 |
Chang, P | 2 |
Peterson, ED | 2 |
Knauf, F | 1 |
Chaknos, CM | 1 |
Berns, JS | 1 |
Perazella, MA | 1 |
Assiri, A | 1 |
Al-Majzoub, O | 1 |
Kanaan, AO | 1 |
Donovan, JL | 1 |
Silva, M | 1 |
Djalali, S | 1 |
Weitz, JI | 4 |
Jennings, JM | 1 |
Robichaux, R | 1 |
McElderry, HT | 1 |
Plumb, VJ | 1 |
Gunter, A | 1 |
Doppalapudi, H | 1 |
Osorio, J | 1 |
Yamada, T | 1 |
Kay, GN | 1 |
Baumann Kreuziger, LM | 2 |
Reding, MT | 1 |
Zalesak, M | 1 |
Siu, K | 1 |
Francis, K | 1 |
Yu, C | 1 |
Alvrtsyan, H | 1 |
Rao, Y | 1 |
Walker, D | 1 |
Sander, S | 1 |
Miyasato, G | 1 |
Matchar, D | 1 |
Sanchez, H | 1 |
Avorn, J | 2 |
Majeed, A | 3 |
Ratanapo, S | 1 |
Ungprasert, P | 1 |
Srivali, N | 1 |
Cheungpasitporn, W | 1 |
Bischof, EF | 1 |
Thomas, PA | 1 |
Schaerf, NB | 1 |
Rosenfeld, JV | 1 |
Granger, CB | 3 |
Kappetein, AP | 1 |
Mack, MJ | 1 |
Blatchford, J | 1 |
Devenny, K | 1 |
Guiver, K | 1 |
Harper, R | 1 |
Khder, Y | 2 |
Lobmeyer, MT | 1 |
Maas, H | 1 |
Voigt, JU | 1 |
Simoons, ML | 1 |
Van de Werf, F | 2 |
Pernod, G | 2 |
Godier, A | 1 |
Susen, S | 1 |
Gruel, Y | 1 |
Blais, N | 1 |
Fontana, P | 2 |
Cohen, A | 2 |
Rosencher, N | 1 |
Schved, JF | 1 |
de Maistre, E | 1 |
Samama, MM | 1 |
Sié, P | 1 |
Castellucci, LA | 1 |
Le Gal, G | 1 |
Rodger, MA | 1 |
Wells, PS | 1 |
Clifford, T | 1 |
Gandara, E | 1 |
Wells, G | 1 |
Carrier, M | 2 |
Ryan, M | 1 |
Ware, K | 1 |
Qamri, Z | 1 |
Satoskar, A | 1 |
Wu, H | 1 |
Nadasdy, G | 1 |
Rovin, B | 1 |
Hebert, L | 1 |
Nadasdy, T | 1 |
Brodsky, SV | 1 |
Adam, SS | 1 |
McDuffie, JR | 1 |
Lachiewicz, PF | 1 |
Ortel, TL | 3 |
Williams, JW | 1 |
Pfeilschifter, W | 1 |
Luger, S | 1 |
Brunkhorst, R | 1 |
Lindhoff-Last, E | 1 |
Foerch, C | 2 |
Schaeffer, S | 1 |
Conway, SE | 3 |
Hwang, HG | 2 |
Fraessdorf, M | 2 |
Chandler, WL | 1 |
Blum, J | 1 |
Carreiro, S | 1 |
Hack, JB | 1 |
Díaz, MQ | 1 |
Borobia, AM | 1 |
Núñez, MA | 1 |
Virto, AM | 1 |
Fabra, S | 1 |
Casado, MS | 1 |
García-Erce, JA | 1 |
Pazmiño, P | 1 |
Yap, LB | 1 |
Rusani, BI | 1 |
Umadevan, D | 1 |
Muhammad, Z | 1 |
Hussin, A | 1 |
Kaur, S | 1 |
Holmes, DN | 1 |
Kowey, PR | 1 |
Hylek, EM | 3 |
Okada, Y | 1 |
Schaeffer, SE | 1 |
Harrison, DL | 1 |
Ragni, MV | 1 |
Clemens, A | 1 |
Noack, H | 1 |
van der Hulle, T | 1 |
Kooiman, J | 1 |
den Exter, PL | 1 |
Dekkers, OM | 1 |
Klok, FA | 1 |
Huisman, MV | 3 |
Verhamme, P | 2 |
Bounameaux, H | 2 |
Christiansen, AV | 1 |
Le Maulf, F | 1 |
Peter, N | 1 |
Aumann, V | 1 |
Boxberger, N | 1 |
Heim, MU | 1 |
Hartung, KJ | 1 |
Siegemund, A | 1 |
Herrmann, R | 1 |
Thom, J | 1 |
Wood, A | 1 |
Phillips, M | 1 |
Muhammad, S | 1 |
Baker, R | 1 |
Bachellerie, B | 1 |
Ruiz, S | 1 |
Conil, JM | 1 |
Crognier, L | 1 |
Seguin, T | 1 |
Georges, B | 1 |
Fourcade, O | 1 |
Ritchie, B | 1 |
Goy, JK | 1 |
Nahirniak, S | 1 |
Almutawa, M | 1 |
Ghanny, S | 1 |
Siegal, DM | 2 |
Garcia, DA | 3 |
Bloom, BJ | 1 |
Filion, KB | 1 |
Atallah, R | 1 |
Eisenberg, MJ | 1 |
Goto, S | 1 |
Tomita, A | 1 |
Kosiuk, J | 1 |
Koutalas, E | 1 |
Doering, M | 1 |
Sommer, P | 1 |
Rolf, S | 1 |
Breithardt, OA | 1 |
Nedios, S | 1 |
Dinov, B | 1 |
Hindricks, G | 1 |
Richter, S | 1 |
Bollmann, A | 1 |
Berthelot, E | 1 |
Lavenu-Bombled, C | 1 |
Orostegui-Giron, L | 1 |
Desconclois, C | 1 |
Assayag, P | 1 |
Miller, MP | 1 |
Trujillo, TC | 1 |
Nordenholz, KE | 1 |
Larsen, TB | 2 |
Gorst-Rasmussen, A | 1 |
Rasmussen, LH | 2 |
Skjøth, F | 2 |
Rosenzweig, M | 1 |
Molinier, A | 1 |
Acket, B | 1 |
Bourrel, R | 1 |
Lavezzi, O | 1 |
Montastruc, JL | 1 |
Bagheri, H | 1 |
Joson, J | 1 |
Nguyen, VT | 1 |
Shah, R | 1 |
Schaefer, JH | 1 |
Leung, W | 1 |
Wu, L | 1 |
Van Cott, EM | 1 |
Lok, J | 1 |
Whalen, M | 1 |
van Leyen, K | 1 |
Lauer, A | 1 |
van Ryn, J | 1 |
Lo, EH | 1 |
Providência, R | 1 |
Marijon, E | 1 |
Albenque, JP | 1 |
Combes, S | 1 |
Combes, N | 1 |
Jourda, F | 1 |
Hireche, H | 1 |
Morais, J | 1 |
Boveda, S | 1 |
Capodanno, D | 1 |
Angiolillo, DJ | 1 |
Brunetti, L | 1 |
Chen, C | 1 |
White, J | 1 |
Wong, H | 1 |
Antoniazzi, S | 1 |
Berdaï, D | 1 |
Conti, V | 1 |
Clementi, E | 1 |
Salvo, F | 1 |
McConeghy, KW | 1 |
Bress, A | 1 |
Qato, DM | 1 |
Wing, C | 1 |
Thachil, J | 2 |
Fenger-Eriksen, C | 1 |
Münster, AM | 1 |
Grove, EL | 1 |
Gallus, A | 1 |
Poller, L | 1 |
Jespersen, J | 1 |
Ibrahim, S | 1 |
Lai, A | 1 |
Davidson, N | 1 |
Galloway, SW | 1 |
Brieger, D | 1 |
Steurer, J | 2 |
Granziera, S | 1 |
Cohen, AT | 1 |
Dempfle, CE | 1 |
Noll, G | 1 |
Noll, S | 1 |
Hürlimann, D | 1 |
Fontaine, GV | 1 |
Mathews, KD | 1 |
Woller, SC | 1 |
Stevens, SM | 1 |
Lloyd, JF | 1 |
Evans, RS | 1 |
Shore, S | 1 |
Carey, EP | 1 |
Turakhia, MP | 2 |
Jackevicius, CA | 1 |
Cunningham, F | 1 |
Pilote, L | 1 |
Bradley, SM | 1 |
Maddox, TM | 1 |
Grunwald, GK | 1 |
Barón, AE | 1 |
Rumsfeld, JS | 1 |
Varosy, PD | 1 |
Schneider, PM | 1 |
Marzec, LN | 1 |
Ho, PM | 1 |
Sølbeck, S | 1 |
Nilsson, CU | 1 |
Engström, M | 1 |
Ostrowski, SR | 1 |
Johansson, PI | 1 |
Lévy, S | 1 |
Joseph, J | 1 |
Young, L | 2 |
McRae, S | 1 |
Curnow, J | 1 |
Nandurkar, H | 1 |
Wood, P | 1 |
McLintock, C | 2 |
Gómez-Outes, A | 1 |
Terleira-Fernández, AI | 1 |
Lecumberri, R | 1 |
Suárez-Gea, ML | 1 |
Vargas-Castrillón, E | 1 |
Cohen, D | 2 |
Charlton, B | 1 |
Redberg, R | 1 |
Alotaibi, G | 1 |
Alsaleh, K | 1 |
Wu, C | 1 |
Mcmurtry, MS | 1 |
Moore, TJ | 1 |
Cohen, MR | 1 |
Mattison, DR | 1 |
Sardar, P | 2 |
Chatterjee, S | 2 |
Herzog, E | 1 |
Nairooz, R | 1 |
Mukherjee, D | 2 |
Amin, A | 2 |
Jing, Y | 1 |
Trocio, J | 1 |
Lin, J | 1 |
Lingohr-Smith, M | 1 |
Graham, J | 1 |
Ho, MH | 1 |
Ho, CW | 1 |
Cheung, E | 1 |
Chan, PH | 1 |
Hai, JJ | 1 |
Chan, KH | 1 |
Chan, EW | 1 |
Leung, GK | 1 |
Tse, HF | 1 |
Siu, CW | 1 |
Vaughan Sarrazin, MS | 1 |
Jones, M | 1 |
Mazur, A | 1 |
Chrischilles, E | 1 |
Cram, P | 1 |
Badal, M | 1 |
Aryal, MR | 1 |
Mege, J | 1 |
Chaudhary, A | 1 |
Donato, AA | 1 |
DeFelipe-Mimbrera, A | 1 |
Alonso Cánovas, A | 1 |
Guillán, M | 2 |
Matute, C | 1 |
Sainz de la Maza, S | 1 |
Cruz, A | 1 |
Vera, R | 1 |
Masjuan, J | 2 |
Stokes, M | 1 |
Makenbaeva, D | 1 |
Wiederkehr, D | 1 |
Wu, N | 1 |
Lawrence, JH | 1 |
Keenan, JC | 1 |
Morton, CT | 1 |
Dries, DJ | 1 |
Kyrle, PA | 1 |
Binder, K | 1 |
Eichinger, S | 1 |
Függer, R | 1 |
Gollackner, B | 1 |
Hiesmayr, JM | 1 |
Lang, W | 1 |
Perger, P | 1 |
Quehenberger, P | 1 |
Roithinger, FX | 1 |
Schmaldienst, S | 1 |
Weltermann, A | 1 |
Domanovits, H | 1 |
Rudakova, AV | 1 |
Tatarskiĭ, BA | 1 |
Hifumi, T | 1 |
Takada, H | 1 |
Kiriu, N | 1 |
Pugi, A | 1 |
Fallani, F | 1 |
Palazzi, N | 1 |
Banfi, R | 1 |
Pluym, M | 1 |
Howell, G | 1 |
Graham, DJ | 1 |
Wernecke, M | 1 |
Zhang, R | 1 |
Levenson, M | 1 |
Sheu, TC | 1 |
Mott, K | 1 |
Goulding, MR | 1 |
Houstoun, M | 1 |
MaCurdy, TE | 1 |
Worrall, C | 1 |
Kelman, JA | 1 |
Redberg, RF | 1 |
Hernandez, I | 2 |
Baik, SH | 1 |
Piñera, A | 1 |
Zhang, Y | 2 |
Baber, U | 1 |
Mastoris, I | 1 |
Mehran, R | 1 |
Beyer-Westendorf, J | 1 |
Snipelisky, D | 2 |
Ray, JC | 1 |
Ung, R | 1 |
Duart, M | 1 |
Kauffman, C | 2 |
Kusumoto, F | 2 |
Bell, AD | 2 |
Liew, A | 1 |
Carney, EF | 1 |
Getta, B | 1 |
Muller, N | 1 |
Motum, P | 1 |
Hsu, D | 1 |
Zebeljan, D | 1 |
Rosenfeld, D | 1 |
Lavie, CJ | 1 |
Giri, JS | 1 |
Ghosh, J | 1 |
Owada, S | 1 |
Tomita, H | 1 |
Kinjo, T | 1 |
Ishida, Y | 1 |
Itoh, T | 1 |
Sasaki, K | 1 |
Horiuchi, D | 1 |
Kimura, M | 1 |
Sasaki, S | 1 |
Okumura, K | 1 |
Davis, EM | 1 |
Uhlmeyer, EM | 1 |
Schmidt, DP | 1 |
Schardt, GL | 1 |
Beliavskaia, OO | 1 |
Vavilova, TV | 1 |
Cairns, JA | 1 |
Hoffman, M | 1 |
Volovyk, Z | 1 |
Monroe, DM | 1 |
Peacock, WF | 1 |
Armbruster, HL | 1 |
Lindsley, JP | 1 |
Moranville, MP | 1 |
Habibi, M | 1 |
Khurram, IM | 1 |
Spragg, DD | 1 |
Berger, RD | 1 |
Calkins, H | 1 |
Marine, JE | 1 |
Gorzelak-Pabiś, P | 1 |
Duraj, I | 1 |
Szlagowska, L | 1 |
Ciastkowska, A | 1 |
Broncel, M | 1 |
Sukovatykh, BS | 1 |
Belikov, LN | 1 |
Savchuk, OF | 1 |
Sukovatykh, MB | 1 |
Blann, AD | 1 |
Moustafa, F | 1 |
Milhaud, G | 1 |
Dublanchet, N | 1 |
Lebreton, A | 1 |
Dutheil, F | 1 |
Schmidt, J | 1 |
Chan, KE | 1 |
Edelman, ER | 1 |
Wenger, JB | 1 |
Thadhani, RI | 1 |
Maddux, FW | 1 |
Karetová, D | 1 |
Bultas, J | 2 |
Rockey, DC | 1 |
Hasler, S | 1 |
Bouchard, J | 1 |
Ghannoum, M | 1 |
Bernier-Jean, A | 1 |
Williamson, D | 1 |
Kershaw, G | 1 |
Weatherburn, C | 1 |
Eris, JM | 1 |
Patel, JP | 2 |
Roberts, DM | 1 |
Liotta, EM | 1 |
Levasseur-Franklin, KE | 1 |
Naidech, AM | 1 |
Kim, B | 1 |
Patel, AD | 1 |
Tan, MK | 1 |
Angaran, P | 1 |
Berall, M | 1 |
Bucci, C | 1 |
Demchuk, AM | 1 |
Essebag, V | 1 |
Goldin, L | 1 |
Green, MS | 1 |
Gregoire, JC | 1 |
Gross, PL | 1 |
Heilbron, B | 1 |
Lin, PJ | 1 |
Ramanathan, K | 1 |
Skanes, A | 1 |
Wheeler, BH | 1 |
Goodman, SG | 1 |
Oberhofer, E | 1 |
Messerschmidt, C | 1 |
Friedman, RJ | 2 |
Lane, DA | 3 |
Wood, K | 1 |
Gehrie, E | 1 |
Tormey, C | 1 |
Lee, AY | 1 |
Shivakumar, S | 1 |
Blostein, M | 1 |
Spencer, FA | 2 |
Solymoss, S | 1 |
Barty, R | 1 |
Wang, G | 1 |
Heddle, N | 1 |
Nagao, T | 1 |
Inden, Y | 1 |
Shimano, M | 1 |
Fujita, M | 1 |
Yanagisawa, S | 1 |
Kato, H | 1 |
Ishikawa, S | 1 |
Miyoshi, A | 1 |
Okumura, S | 1 |
Ohguchi, S | 1 |
Yamamoto, T | 1 |
Yoshida, N | 1 |
Hirai, M | 1 |
Murohara, T | 1 |
Chang, TW | 1 |
Arpey, CJ | 1 |
Baum, CL | 1 |
Brewer, JD | 1 |
Hochwalt, PC | 1 |
Hocker, TL | 1 |
Roenigk, RK | 1 |
Otley, CC | 1 |
Bauer, KA | 1 |
Glund, S | 1 |
Bernstein, RA | 1 |
Dubiel, R | 1 |
Kreuzer, J | 2 |
Sellke, FW | 1 |
Stangier, J | 1 |
Wang, B | 1 |
Kam, CW | 1 |
Miyares, MA | 2 |
Horjus, DL | 1 |
van Montfrans, GA | 1 |
Brewster, LM | 1 |
Klil-Drori, A | 1 |
Azoulay, L | 1 |
Zint, K | 1 |
Liu, S | 1 |
Kim, CO | 1 |
Lucyk, SN | 1 |
Henriksen, DP | 1 |
Hansen, MR | 1 |
Damkier, P | 1 |
Zeus, T | 1 |
Kelm, M | 1 |
Bode, C | 1 |
Lavine, JB | 1 |
Torjesen, I | 1 |
Heard, LK | 1 |
Shanahan, C | 1 |
Maggio, KL | 1 |
Escobar, C | 2 |
Barrios, V | 2 |
Jimenez, D | 1 |
Romualdi, E | 1 |
Rancan, E | 1 |
Siragusa, S | 2 |
Ageno, W | 1 |
Quinlan, DJ | 1 |
Dahl, OE | 3 |
Freeman, JV | 1 |
Zhu, RP | 1 |
Owens, DK | 1 |
Garber, AM | 1 |
Hutton, DW | 1 |
Wang, PJ | 1 |
Oliver, M | 1 |
Loke, YK | 1 |
Kwok, CS | 1 |
Nagarakanti, R | 1 |
Chernick, M | 1 |
Aikens, TH | 1 |
Flaker, G | 1 |
Brugada, J | 1 |
Parekh, A | 1 |
Eriksson, BI | 1 |
Huo, MH | 1 |
Kurth, AA | 1 |
Hantel, S | 1 |
Hermansson, K | 1 |
Schnee, JM | 1 |
Hori, M | 1 |
Beasley, BN | 1 |
Temple, R | 1 |
Matute, MC | 1 |
García-Caldentey, J | 1 |
Buisan, J | 1 |
Aparicio, M | 1 |
Alonso de Leciñana, M | 1 |
Budaj, A | 1 |
Roberts, J | 1 |
Siegbahn, A | 1 |
Tijssen, JG | 1 |
Kaatz, S | 2 |
Varrone, J | 1 |
Shah, SV | 1 |
Gage, BF | 1 |
Welzel, D | 1 |
Hull, R | 1 |
Fareed, J | 1 |
Lee, TH | 1 |
Kazmi, RS | 1 |
Lwaleed, BA | 1 |
Gage, L | 1 |
Roberts, LN | 1 |
Arya, R | 1 |
Babu, KM | 1 |
Brown, RS | 1 |
Boyer, EW | 1 |
Hunchuck, JE | 1 |
Lake, JD | 1 |
Pengo, V | 2 |
Crippa, L | 2 |
Falanga, A | 2 |
Finazzi, G | 2 |
Marongiu, F | 2 |
Palareti, G | 2 |
Poli, D | 2 |
Testa, S | 2 |
Tiraferri, E | 2 |
Tosetto, A | 2 |
Tripodi, A | 3 |
Manotti, C | 2 |
Winkle, RA | 1 |
Mead, RH | 1 |
Engel, G | 1 |
Kong, MH | 1 |
Patrawala, RA | 1 |
Weimar, C | 1 |
Augoustides, JG | 1 |
Jolobe, OM | 1 |
Beyth, RJ | 1 |
Landefeld, CS | 1 |
Cotton, BA | 1 |
McCarthy, JJ | 1 |
Holcomb, JB | 1 |
Panchenko, EP | 1 |
Moore, CH | 1 |
Snashall, J | 1 |
Boniface, K | 1 |
Scott, J | 1 |
Govindarajan, R | 1 |
Salgado, E | 1 |
Reynolds, S | 1 |
Parra, D | 1 |
Rosenstein, RS | 1 |
Reiffel, JA | 1 |
Suzuki, S | 1 |
Otsuka, T | 1 |
Sagara, K | 1 |
Matsuno, S | 1 |
Funada, R | 1 |
Uejima, T | 1 |
Oikawa, Y | 1 |
Yajima, J | 1 |
Koike, A | 1 |
Nagashima, K | 1 |
Kirigaya, H | 1 |
Sawada, H | 1 |
Aizawa, T | 1 |
Yamashita, T | 1 |
Tendera, M | 1 |
Syzdół, M | 1 |
Parma, Z | 1 |
Lakkireddy, D | 1 |
Reddy, YM | 1 |
Di Biase, L | 1 |
Vanga, SR | 1 |
Santangeli, P | 1 |
Swarup, V | 1 |
Pimentel, R | 1 |
Mansour, MC | 1 |
D'Avila, A | 1 |
Sanchez, JE | 1 |
Burkhardt, JD | 1 |
Chalhoub, F | 1 |
Mohanty, P | 1 |
Coffey, J | 1 |
Shaik, N | 1 |
Monir, G | 1 |
Reddy, VY | 1 |
Ruskin, J | 1 |
Natale, A | 1 |
You, JJ | 1 |
Howard, PA | 1 |
Eckman, MH | 1 |
Fang, MC | 1 |
Hughes, M | 1 |
Manning, WJ | 1 |
Lip, GYH | 1 |
Comin, J | 1 |
Kallmes, DF | 1 |
Soff, GA | 1 |
Harper, P | 2 |
Merriman, E | 1 |
Ali, A | 1 |
Bailey, C | 1 |
Abdelhafiz, AH | 1 |
Cano, EL | 1 |
Drost, P | 1 |
Marchant, N | 1 |
Mitchell, S | 1 |
Orme, M | 1 |
Rublee, D | 1 |
Simon, TA | 1 |
Sutton, A | 1 |
Nieto, JA | 1 |
Espada, NG | 1 |
Merino, RG | 1 |
González, TC | 1 |
Baker, RI | 1 |
Schomburg, JL | 1 |
Medina, EM | 1 |
Lahti, MT | 1 |
Bianco, RW | 1 |
Mustonen, P | 1 |
Puurunen, M | 1 |
Ilmakunnas, M | 1 |
Louhimo, J | 1 |
Lassila, R | 1 |
Varughese, CJ | 1 |
Lewalter, T | 1 |
Little, JW | 1 |
Gil Núñez, A | 1 |
Zapata Wainberg, G | 1 |
Ximénez-Carrillo Rico, A | 1 |
Vivancos Mora, J | 1 |
Heidbuchle, H | 1 |
Kar, S | 1 |
Bhatt, DL | 1 |
Mantha, S | 1 |
Radecki, RP | 1 |
Schneeweiss, S | 1 |
Gagne, JJ | 1 |
Patrick, AR | 1 |
Choudhry, NK | 1 |
Bilen, O | 1 |
Teruya, J | 1 |
Moia, M | 1 |
Huang, C | 1 |
Siu, M | 1 |
Vu, L | 1 |
Wong, S | 1 |
Shin, J | 1 |
Shevelev, VI | 2 |
Kanorskiĭ, SG | 1 |
Husari, A | 1 |
Beydoun, A | 1 |
Sheik Ammar, A | 1 |
Maakaron, JE | 1 |
Taher, A | 1 |
Prussak, K | 1 |
Johns, G | 1 |
Venkatachalam, K | 1 |
Kosar, L | 1 |
Jin, M | 1 |
Kamrul, R | 1 |
Schuster, B | 1 |
Alonso-Coello, P | 1 |
Zhou, Q | 1 |
Guyatt, G | 1 |
Spyropoulos, AC | 1 |
Gerotziafas, G | 1 |
Viny, AD | 1 |
Garlich, FM | 1 |
Basciano, P | 1 |
Howland, MA | 1 |
Yokoi, K | 1 |
Isoda, K | 1 |
Kimura, T | 1 |
Adachi, T | 1 |
Harenberg, J | 1 |
Marx, S | 1 |
Marder, VJ | 1 |
Schulze, A | 1 |
Wehling, M | 1 |
Weiss, C | 1 |
Ehrenschwender, M | 1 |
Koessler, J | 1 |
Brunner, K | 1 |
Steigerwald, U | 1 |
Esmon, CT | 1 |
Kawaguchi, K | 1 |
Lambein, F | 1 |
Kusama-Eguchi, K | 1 |
Tafur, A | 1 |
Wysokinski, WE | 1 |
McBane, RD | 1 |
Aalbers, J | 1 |
Hardy, G | 1 |
Furman, NV | 1 |
Kuvshinova, LE | 1 |
Dovgalevskiĭ, IaP | 1 |
Obeng-Gyasi, S | 1 |
Loor, MM | 1 |
Samotowka, MA | 1 |
Moorman, ML | 1 |
Pieracci, FM | 1 |
Haschke, M | 1 |
Pisters, R | 1 |
Nieuwlaat, R | 1 |
Crijns, HJ | 1 |
Pawlikowska, Z | 1 |
Szponar, J | 1 |
Kanorsky, SG | 1 |
Deitelzweig, SB | 1 |
Best, M | 1 |
Palmer, K | 1 |
Jones, QC | 1 |
Wathen, CG | 1 |
Huang, GS | 1 |
Chance, EA | 1 |
Gómez Arrayas, I | 1 |
Suárez Fernández, C | 1 |
Gómez Cerezo, JF | 1 |
Betegón Nicolás, L | 1 |
de Salas-Cansado, M | 1 |
Rubio-Terrés, C | 1 |
Livio, F | 1 |
Brem, E | 1 |
Koyfman, A | 1 |
Foran, M | 1 |
Breik, O | 1 |
Tadros, R | 1 |
Devitt, P | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Prothrombin Complex Concentrate (PCC) Compared to Fresh Frozen Plasma (FFP) for Post-cardiopulmonary Bypass Coagulopathy and Bleeding, a Prospective Randomized Trial at Large US Medical Center.[NCT02557672] | Phase 4 | 106 participants (Actual) | Interventional | 2016-08-31 | Completed | ||
Investigation of Genetic Variations on Patients With Adverse Events While on Direct Oral Anticoagulants (DOACs)[NCT04580589] | 210 participants (Actual) | Observational | 2021-02-01 | Completed | |||
Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long-term Prevention of Recurrent Symptomatic Proximal Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism.[NCT00558259] | Phase 3 | 1,353 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous Thromboembo[NCT00329238] | Phase 3 | 2,867 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis[NCT04981327] | Phase 3 | 1,300 participants (Anticipated) | Interventional | 2022-09-01 | Not yet recruiting | ||
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atria[NCT00262600] | Phase 3 | 18,113 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomised Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes[NCT00808067] | Phase 3 | 5,897 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
An Epidemiological Study to Evaluate the Use of Vitamin K Antagonists and New Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients in Turkey[NCT02354456] | 4,100 participants (Anticipated) | Observational [Patient Registry] | 2015-01-31 | Recruiting | |||
Prospective Observational Study of the Direct Oral Anticoagulants Periprocedural Management[NCT03182218] | 1,100 participants (Actual) | Observational | 2015-02-28 | Completed | |||
Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm (BOAT OAR)[NCT03515083] | 100 participants (Actual) | Interventional | 2017-07-17 | Completed | |||
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)[NCT01165710] | 10,179 participants (Actual) | Observational | 2010-06-30 | Completed | |||
This is a Prospective, Open-label Phase 2 Pilot Study With Independent Evaluation of All Outcomes and a Historical Control Group to Determine if Rivaroxaban (Xarelto) is Feasible and Safe for Prevention of Major Complications in Patients Undergoing a Mech[NCT02128841] | Phase 2 | 12 participants (Actual) | Interventional | 2012-09-30 | Terminated (stopped due to not enough patients) | ||
A Prospective, Randomized, Active (Warfarin) Controlled, Parallel-arm Clinical Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely and Effectively on Apixaban[NCT04142658] | Phase 3 | 863 participants (Actual) | Interventional | 2020-05-01 | Terminated (stopped due to Safety) | ||
Pharmacogenetic Algorithm of Response to Warfarin During Initial Anticoagulation in Chinese Elderly Patients[NCT02211326] | 660 participants (Actual) | Interventional | 2014-09-01 | Completed | |||
Evaluation of the Long Term Safety of the Use of Dabigatran Etexilate in Patients With a Bileaflet Mechanical Heart Valve[NCT01505881] | Phase 2 | 158 participants (Actual) | Interventional | 2011-12-31 | Terminated | ||
A Randomised, Phase II Study to Evaluate the sAfety and Pharmacokinetics of oraL dabIGatran Etexilate in Patients After Heart Valve replacemeNt[NCT01452347] | Phase 2 | 328 participants (Actual) | Interventional | 2011-10-31 | Terminated | ||
Can Rivaroxaban Lead to Anticoagulation-Related Nephropathy?[NCT02900170] | 8 participants (Actual) | Observational | 2016-07-31 | Completed | |||
A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism, Following Initial Treatm[NCT00680186] | Phase 3 | 2,589 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate 150 mg Twice Daily Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism (VTE), Following In[NCT00291330] | Phase 3 | 2,564 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
The Prevalence of Post-Thrombotic Syndrome in Deep-Vein Thrombosis (DVT) Patients Treated With Dabigatran- a Cross-Sectional Assessment of RE-COVER Study Patients[NCT03050138] | 351 participants (Actual) | Observational | 2016-04-30 | Completed | |||
Early Administration of Edoxaban After Acute Ischemic Stroke in Patients With Non-valvular Atrial Fibrillation: a Randomized, Multi-center, Parallel-group Trial (PILOT)[NCT03433235] | Phase 2 | 68 participants (Actual) | Interventional | 2018-06-19 | Completed | ||
Effectivity of a Joint Didactic Intervention by School for Patients on Inappropriate Control Prothrombin Time Anticoagulated Patients. Protocol for Developing a Randomized and Controlled Clinical Trial[NCT03647254] | 1 participants (Anticipated) | Interventional | 2018-09-01 | Recruiting | |||
A Monitor System for the Safety of Dabigatran Anticoagulation Treatment in Nonvalvular Atrial Fibrillation[NCT02414035] | 1,496 participants (Actual) | Observational | 2015-03-22 | Completed | |||
Pilot Intervention to Improve Adherence to Dabigatran for Patients With Atrial Fibillation[NCT01578044] | 12 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation[NCT04357288] | 1,200 participants (Anticipated) | Interventional | 2020-12-16 | Active, not recruiting | |||
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial[NCT02942407] | Phase 4 | 154 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
A Phase III Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0g Idarucizumab (BI 655075) in Patients Treated Wtih Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emerge[NCT02104947] | Phase 3 | 503 participants (Actual) | Interventional | 2014-05-06 | Completed | ||
A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Orally Administered 220 mg Dabigatran Etexilate Capsules (110 mg Administered on the Day of Surgery Followed by 220 mg Once Daily) Comp[NCT00657150] | Phase 3 | 2,055 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2018-05-01 | Recruiting | |||
Comparison of Accidents and Their Circumstances With Oral Anticoagulants. The CACAO Study[NCT02376777] | 4,162 participants (Actual) | Observational | 2014-04-30 | Completed | |||
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation[NCT03021928] | Phase 3 | 200 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
Anticoagulant-associated Intracranial Hemorrhage: Patient Characteristics and Outcomes From National Institute of Neurology and Neurosurgery Manuel Velasco: Single-Center Observational Study[NCT06168838] | 1,200 participants (Anticipated) | Observational | 2023-08-09 | Recruiting | |||
Prospective Study of the Assessment of the Dental Protocol for Tooth Extraction in Patients With Atrial Fibrillation in Continuous Use of New Oral Anticoagulants: A Pilot Study[NCT03181386] | Phase 3 | 60 participants (Actual) | Interventional | 2017-05-03 | Completed | ||
Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants[NCT02185027] | 1,166 participants (Actual) | Observational | 2013-06-30 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The amount of chest tube drainage output from after surgery through midnight of the next day. As measured in mL. (NCT02557672)
Timeframe: 24 hours
Intervention | mL (Median) |
---|---|
Fresh Frozen Plasma | 1022 |
Prothrombin Complex Concentrate | 937 |
The number of subject's who received 0,1,2,3 or more units of Cryo's transfused from completion of study drug administration though midnight of the next day. (NCT02557672)
Timeframe: 24 hours
Intervention | Participants (Count of Participants) | |||
---|---|---|---|---|
0 units | 1 unit | 2 units | 3 or more units | |
Fresh Frozen Plasma | 40 | 2 | 5 | 1 |
Prothrombin Complex Concentrate | 40 | 2 | 8 | 1 |
The number of subject's who received 0,1,2,3 or more units of FFP's transfused from completion of study drug administration though midnight of the next day. (NCT02557672)
Timeframe: 24 hours
Intervention | Participants (Count of Participants) | |||
---|---|---|---|---|
0 units | 1 unit | 2 units | 3 or more units | |
Fresh Frozen Plasma | 43 | 0 | 4 | 1 |
Prothrombin Complex Concentrate | 48 | 1 | 2 | 0 |
The number of subject's who received 0,1,2,3 or more units of Platelets transfused from completion of study drug administration though midnight of the next day. (NCT02557672)
Timeframe: 24 hours
Intervention | Participants (Count of Participants) | |||
---|---|---|---|---|
0 units | 1 unit | 2 units | 3 or more units | |
Fresh Frozen Plasma | 30 | 13 | 3 | 2 |
Prothrombin Complex Concentrate | 36 | 9 | 3 | 3 |
The number of subject's who received 0,1,2,3 or more units of RBC's transfused from completion of study drug administration though midnight of the next day. (NCT02557672)
Timeframe: 24 hours
Intervention | Participants (Count of Participants) | |||
---|---|---|---|---|
0 units | 1 unit | 2 units | 3 or more units | |
Fresh Frozen Plasma | 26 | 11 | 6 | 5 |
Prothrombin Complex Concentrate | 36 | 8 | 5 | 2 |
Cardiovascular events that occurred during the treatment period + 3 days were summarised by treatment groups. (NCT00558259)
Timeframe: 6 months
Intervention | participants (Number) |
---|---|
Dabigatran | 3 |
Placebo | 2 |
Number of participants with centrally confirmed symptomatic pulmonary embolism (PE) events during the intended treatment period were described. (NCT00558259)
Timeframe: 6 months
Intervention | Participants (Number) |
---|---|
Dabigatran | 1 |
Placebo | 14 |
Number of the participants with centrally confirmed symptomatic recurrent deep venous thrombotic (DVT) events during the intended treatment period were described. (NCT00558259)
Timeframe: 6 months
Intervention | Participants (Number) |
---|---|
Dabigatran | 2 |
Placebo | 23 |
Symptomatic recurrent VTE is the composite of recurrent deep vein thrombosis (DVT) , fatal or non-fatal pulmonary embolism (PE). Whilst the endpoint is time to event, the measured values present the number of participant with event and the hazard ratio presents the time to event. (NCT00558259)
Timeframe: 6 months
Intervention | Participants (Number) |
---|---|
Dabigatran | 3 |
Placebo | 35 |
Symptomatic recurrent VTE is the composite of recurrent deep vein thrombosis (DVT) , fatal or non-fatal pulmonary embolism (PE). Whilst the endpoint is time to event, the measured values present the number of participant with event and the hazard ratio presents the time to event. (NCT00558259)
Timeframe: 6 months
Intervention | Participants (Number) |
---|---|
Dabigatran | 3 |
Placebo | 37 |
Number of participants with centrally confirmed unexplained deaths during the intended treatment period were described. (NCT00558259)
Timeframe: 6 months
Intervention | participants (Number) |
---|---|
Dabigatran | 0 |
Placebo | 2 |
"Major bleeding events (MBE) had to fulfil at least 1 of the following criteria:~Fatal bleeding~Associated with a fall in haemoglobin of ≥2 g/dL~Led to the transfusion of ≥2 units packed cells or whole blood~Occurred in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal~Other clinically relevant bleeding was defined as overt bleeding not meeting the criteria for an MBE but associated with medical intervention, unscheduled contact with a physician, (temporary) cessation of study treatment, or associated with discomfort such as pain, or impairment of activities of daily life.~Examples of these bleedings were:~Bleeding that compromised haemodynamics~Bleeding that led to hospitalisation~Trivial bleeding events were defined as all other bleeding events that did not fulfil the criteria of MBEs or CRBEs.~All bleeding events include MBEs, CRBEs, and trivial bleeding events." (NCT00558259)
Timeframe: 6 months
Intervention | participants (Number) | ||
---|---|---|---|
MBE | MBE or CRBE | All Bleeding | |
Dabigatran | 2 | 36 | 72 |
Placebo | 0 | 12 | 39 |
Number of participants with possible clinically significant abnormalities during the treatment period. (NCT00558259)
Timeframe: 6 months
Intervention | participants (Number) | |||
---|---|---|---|---|
AST increase (N=655, 629) | ALT increase (N=655, 629) | Alkaline phosphatase increase (N=658, 629) | Total bilirubin increase (N=658, 628) | |
Dabigatran | 2 | 3 | 0 | 1 |
Placebo | 2 | 5 | 0 | 1 |
Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. (NCT00329238)
Timeframe: 18 months
Intervention | Participants (Number) | |
---|---|---|
Number of participants with event | Number of participants with no event | |
Dabigatran | 36 | 1394 |
Warfarin | 32 | 1394 |
Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. (NCT00329238)
Timeframe: 36 months
Intervention | Participants (Number) | |
---|---|---|
Number of participants with event | Number of participants with no event | |
Dabigatran | 42 | 1388 |
Warfarin | 36 | 1390 |
Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. In case of death, autopsy was an additional way to confirm VTE. (NCT00329238)
Timeframe: 18 months
Intervention | Participants (Number) | |
---|---|---|
Number of participants with event | Number of participants with no event | |
Dabigatran | 22 | 1408 |
Warfarin | 17 | 1409 |
Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. In case of death, autopsy was an additional way to confirm VTE. (NCT00329238)
Timeframe: 36 months
Intervention | Participants (Number) | |
---|---|---|
Number of participants with event | Number of participants with no event | |
Dabigatran | 26 | 1404 |
Warfarin | 18 | 1408 |
Deaths of all causes at 18 Months. All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments. (NCT00329238)
Timeframe: 18 months
Intervention | Participants (Number) | |
---|---|---|
Number of participants with event | Number of participants with no event | |
Dabigatran | 15 | 1415 |
Warfarin | 16 | 1410 |
Deaths of all causes at 36 Months. All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments. (NCT00329238)
Timeframe: 36 months
Intervention | Participants (Number) | |
---|---|---|
Number of participants with event | Number of participants with no event | |
Dabigatran | 17 | 1413 |
Warfarin | 19 | 1407 |
Deaths related to VTE (i.e. fatal PE) at 18 Months. All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way. (NCT00329238)
Timeframe: 18 months
Intervention | Participants (Number) | |
---|---|---|
Number of participants with event | Number of participants with no event | |
Dabigatran | 1 | 1429 |
Warfarin | 1 | 1425 |
Deaths related to VTE (i.e. fatal PE) at 36 Months. Deaths related to VTE (i.e. fatal PE) at 18 Months. All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way. (NCT00329238)
Timeframe: 36 months
Intervention | Participants (Number) | |
---|---|---|
Number of participants with event | Number of participants with no event | |
Dabigatran | 1 | 1429 |
Warfarin | 1 | 1425 |
Symptomatic Deep vein thrombosis (DVT). All DVT events required objective verification through definitive diagnostic evaluation. (NCT00329238)
Timeframe: 36 months
Intervention | Participants (Number) | |
---|---|---|
Number of participants with event | Number of participants with no event | |
Dabigatran | 17 | 1413 |
Warfarin | 13 | 1413 |
Symptomatic Deep vein thrombosis (DVT). All DVT events required objective verification through definitive diagnostic evaluation. (NCT00329238)
Timeframe: 18 months
Intervention | Participants (Number) | |
---|---|---|
Number of participants with event | Number of participants with no event | |
Dabigatran | 15 | 1415 |
Warfarin | 12 | 1414 |
Patients with LFT (liver function tests) increases of possible clinical significance during treatment. Increases of possible clinical significance were defined as: ≥3 x ULN (AST, ALT), ≥2 x ULN (AP), and ≥2 mg/dL (total bilirubin). Only patients with a baseline value which was not of possible clinical significance (or without any baseline value) could have a PCSA (Possible clinically significant abnormality). (NCT00329238)
Timeframe: 18 months + 30 days follow up
Intervention | participants (Number) | |||
---|---|---|---|---|
ALT increase | AST increase | Alkaline phosphatase | Total bilirubin | |
Dabigatran | 26 | 23 | 9 | 9 |
Warfarin | 30 | 23 | 14 | 8 |
"MBE (major bleeding event) if it fulfilled at least one of the following criteria~Fatal bleeding~Symptomatic bleeding in a critical area or organ.~Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells.~Minor bleeding event was any bleeding that did not fulfil any of the criteria for MBEs~CRBE (clinically relevant bleeding event) if it is a minor bleeding events which fulfilled at least one of the following criteria~Spontaneous skin haematoma ≥25 cm2~Spontaneous nose bleed >5 min duration~Macroscopic haematuria, either spontaneous or, if associated with an intervention, lasting >24 h~Spontaneous rectal bleeding~Gingival bleeding >5 min~Bleeding leading to hospitalisation or requiring surgical treatment~Bleeding leading to a transfusion of <2 units of whole blood or red cells~Any other bleeding event considered clinically relevant by the investigator" (NCT00329238)
Timeframe: first intake of study drug until 6 days following last intake of study drug
Intervention | participants (Number) | ||
---|---|---|---|
patients with MBE | patients with MBE and /or CRBE | patients with any bleeding event | |
Dabigatran | 13 | 80 | 277 |
Warfarin | 25 | 145 | 373 |
All suspected ACS occurring during the trial were to be recorded on the CRF and were to be centrally adjudicated by an independent ACS/AC in a treatment-blinded manner. (NCT00329238)
Timeframe: day of first study drug intake until last day of study drug intake; from the day after last intake of study drug until trial termination
Intervention | participants (Number) | |
---|---|---|
During intake of study drug, N=1430 , N=1415 | After stopping study drug, N=1426, N=1400 | |
Dabigatran | 12 | 1 |
Warfarin | 2 | 5 |
Symptomatic pulmonary embolism (PE) at 18 Months (fatal or non-fatal). All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography. (NCT00329238)
Timeframe: 18 months
Intervention | Participants (Number) | |
---|---|---|
Number of participants with event | Number of participants with no event | |
Dabigatran | 8 | 1422 |
Warfarin | 5 | 1421 |
Symptomatic pulmonary embolism (PE) at 36 Months (fatal or non-fatal). All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography. (NCT00329238)
Timeframe: 36 months
Intervention | Participants (Number) | |
---|---|---|
Number of participants with event | Number of participants with no event | |
Dabigatran | 10 | 1420 |
Warfarin | 5 | 1421 |
Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST>3xULN and total bilirubin > 2 x ULN (NCT00262600)
Timeframe: 36 months
Intervention | participants (Number) |
---|---|
Dabigatran 110 mg | 11 |
Dabigatran 150 mg | 14 |
Warfarin | 21 |
Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
Intervention | yearly event rate (percentage) (Number) |
---|---|
Dabigatran 110 mg | 1.54 |
Dabigatran 150 mg | 1.11 |
Warfarin | 1.71 |
Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
Intervention | yearly event rate (percentage) (Number) |
---|---|
Dabigatran 110 mg | 4.85 |
Dabigatran 150 mg | 4.32 |
Warfarin | 5.20 |
Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
Intervention | yearly event rate (percentage) (Number) |
---|---|
Dabigatran 110 mg | 4.26 |
Dabigatran 150 mg | 3.68 |
Warfarin | 4.35 |
"Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25~Major bleeds are adjudicated, whereas minor bleeds are investigator reported." (NCT00262600)
Timeframe: 36 months
Intervention | yearly event rate (percentage) (Number) | |
---|---|---|
Major bleeds | Minor bleeds | |
Dabigatran 110 mg | 2.99 | 13.16 |
Dabigatran 150 mg | 3.55 | 14.85 |
Warfarin | 3.81 | 16.37 |
Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH) (NCT00262600)
Timeframe: 36 months
Intervention | yearly event rate (percentage)] (Number) | |
---|---|---|
intracerebral hemorrhage | intracranial hemorrhage (ICH) | |
Dabigatran 110 mg | 0.12 | 0.23 |
Dabigatran 150 mg | 0.10 | 0.32 |
Warfarin | 0.38 | 0.76 |
"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~a. In subjects not undergoing PCI or CABG a subject should have fulfilled at least 2 of the following: i. Typical prolonged severe chest pain or related symptoms or signs suggestive of MI. ii. Elevation of troponin or CK-MB to more than upper level of normal (ULN) or, if CK-MB was elevated at baseline, re-elevation to more than 50% increase above the previous level. iii. Development of significant Q-waves in at least 2 adjacent ECG leads. b. After percutaneous coronary intervention (within 24h). c. After coronary artery bypass grafting (within 72h). d. Silent myocardial infarction. e. Myocardial infarction could also have been demonstrated at autopsy." (NCT00808067)
Timeframe: up to 43 months
Intervention | percentage of subject-years (Number) |
---|---|
Dabigatran 110 mg | 0.72 |
Dabigatran 150 mg | 0.66 |
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months
Intervention | percentage of subject-years (Number) |
---|---|
Dabigatran 110 mg | 9.44 |
Dabigatran 150 mg | 11.20 |
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months
Intervention | percentage of subject-years (Number) |
---|---|
Dabigatran 110 mg | 1.60 |
Dabigatran 150 mg | 1.47 |
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months
Intervention | percentage of subject-years (Number) |
---|---|
Dabigatran 110 mg | 4.40 |
Dabigatran 150 mg | 4.02 |
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months
Intervention | percentage of subject-years (Number) |
---|---|
Dabigatran 110 mg | 6.65 |
Dabigatran 150 mg | 7.14 |
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months
Intervention | percentage of subject-years (Number) |
---|---|
Dabigatran 110 mg | 3.51 |
Dabigatran 150 mg | 3.32 |
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months
Intervention | percentage of subject-years (Number) |
---|---|
Dabigatran 110 mg | 0.28 |
Dabigatran 150 mg | 0.33 |
"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Minor bleeds were clinical bleeds that did not fulfill the criteria for major bleeds. Minor bleeds were classified as associated with study medication discontinuation (temporary or permanent) or not." (NCT00808067)
Timeframe: up to 43 months
Intervention | percentage of subject-years (Number) |
---|---|
Dabigatran 110 mg | 7.49 |
Dabigatran 150 mg | 8.98 |
"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Deaths were classified as being vascular (sudden/arrhythmic, pump failure death, or other vascular, including bleeding) or non-vascular, due to other specified causes (e.g., malignancy), or of unknown etiology." (NCT00808067)
Timeframe: up to 43 months
Intervention | percentage of subject-years (Number) |
---|---|
Dabigatran 110 mg | 3.18 |
Dabigatran 150 mg | 2.99 |
"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Deep Vein Thrombosis (DVT) was generally documented by one of the following:~abnormal compression ultrasound (CUS),~an intraluminal filling defect on venography." (NCT00808067)
Timeframe: up to 43 months
Intervention | percentage of subject-years (Number) |
---|---|
Dabigatran 110 mg | 0.06 |
Dabigatran 150 mg | 0.11 |
"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Major bleeding must have satisfied one or more of the following criteria:~Bleeding associated with a reduction in hemoglobin of at least 20 g/L~Required transfusion of at least 2 units of blood or packed cells~Symptomatic bleeding in a critical area or organ: intraocular, intraspinal, intramuscular with compartment syndrome, retroperitoneal, intra-articular, pericardial, gastrointestinal~Major bleed were classified as life-threatening if they met one or more of the following criteria:~Reduction in hemoglobin of at least 50 g/L~Transfusion of at least 4 units of blood or packed cells~Symptomatic intracranial bleeding, either subdural or intracerebral~Associated with hypotension requiring use of intravenous inotropic agents~Required surgical intervention to stop bleeding~Resulted in death" (NCT00808067)
Timeframe: up to 43 months
Intervention | percentage of subject-years (Number) |
---|---|
Dabigatran 110 mg | 2.79 |
Dabigatran 150 mg | 3.59 |
"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Systemic embolism was an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts), and was to be documented by angiography, surgery, scintigraphy, or autopsy." (NCT00808067)
Timeframe: up to 43 months
Intervention | percentage of subject-years (Number) |
---|---|
Dabigatran 110 mg | 0.25 |
Dabigatran 150 mg | 0.23 |
"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Pulmonary Embolism was generally documented by one of the following:~an intraluminal filling defect in segmental or more proximal branches on spiral CT scan~an intraluminal filling defect or an extension of an existing defect or a sudden cutoff of vessels more than 2.5 mm in diameter on the pulmonary angiogram~a perfusion defect of at least 75% of a segment with a local normal ventilation result (high-probability) on ventilation/perfusion lung scan (VPLS)~inconclusive spiral CT, pulmonary angiography or lung scintigraphy with demonstration of DVT in the lower extremities by compression ultrasound or venography." (NCT00808067)
Timeframe: up to 43 months
Intervention | percentage of subject-years (Number) |
---|---|
Dabigatran 110 mg | 0.10 |
Dabigatran 150 mg | 0.12 |
"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Stroke was an acute onset of a focal neurological deficit of presumed vascular origin lasting for 24 hours or more or resulting in death. The stroke was categorized as ischemic or hemorrhagic or cause unknown based on computerized tomography (CT), magnetic resonance (MR) scanning or autopsy. Fatal stroke was defined as death from any cause within 30 days of stroke. Severity of stroke was assessed by modified Rankin score at discharge from hospital" (NCT00808067)
Timeframe: up to 43 months
Intervention | percentage of subject-years (Number) |
---|---|
Dabigatran 110 mg | 1.39 |
Dabigatran 150 mg | 1.26 |
"Percentage of patients with Adverse Events leading to discontinuation of trial drug.~Prespecified clinical outcome events were not recorded as Adverse Events." (NCT01505881)
Timeframe: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)
Intervention | percentage of participants (Number) |
---|---|
Dabigatran Etexilate (DE) | 5.1 |
Warfarin | 1.7 |
Percentage of patients with Adverse Events. Prespecified clinical outcome events were not recorded as Adverse Events. (NCT01505881)
Timeframe: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)
Intervention | percentage of participants (Number) |
---|---|
Dabigatran Etexilate (DE) | 39.4 |
Warfarin | 37.3 |
Percentage of patients with Serious Adverse Events (SAE). Prespecified clinical outcome events were not recorded as Adverse Events. (NCT01505881)
Timeframe: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)
Intervention | percentage of participants (Number) |
---|---|
Dabigatran Etexilate (DE) | 3.0 |
Warfarin | 6.8 |
"Clinical efficacy outcome events presented are:~Death, Venous thromboembolism (VTE), Myocardial Infarction (MI), Transient Ischaemic Attack (TIA), Stroke, Systemic embolism and Valve thrombosis" (NCT01505881)
Timeframe: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)
Intervention | percentage of participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Death | Venous thromboembolism | Myocardial Infarction | Transient Ischaemic Attack | Stroke | Systemic embolism | Valve thrombosis | |
Dabigatran Etexilate (DE) | 0.0 | 0.0 | 1.0 | 1.0 | 3.0 | 0.0 | 2.0 |
Warfarin | 1.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
"Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE).~(As the trial was stopped prematurely, EOT may not be 12 weeks after randomisation for most of the patients)~Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population." (NCT01452347)
Timeframe: Week 12
Intervention | ng/mL (Geometric Mean) |
---|---|
Observed | 108.21 |
Predicted | 104.80 |
"Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE).~Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population." (NCT01452347)
Timeframe: Week 2
Intervention | ng/mL (Geometric Mean) |
---|---|
Observed | 84.08 |
Predicted | 99.55 |
"Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE).~Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population." (NCT01452347)
Timeframe: Week 4
Intervention | ng/mL (Geometric Mean) |
---|---|
Observed | 104.43 |
Predicted | 109.36 |
"Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE) .~Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population." (NCT01452347)
Timeframe: Week 1
Intervention | ng/mL (Geometric Mean) |
---|---|
Observed | 73.86 |
Predicted | 99.52 |
Percentage of patients with observed Ctrough,ss value < 50 ng/mL (As the trial was stopped prematurely, EOT may not be 12 weeks after randomisation for most of the patients) This outcome measure was only analysed for all patients together and not by dose group. (NCT01452347)
Timeframe: Week 12
Intervention | percentage of participants (Number) |
---|---|
Patients Evaluated | 7.4 |
Percentage of patients with observed Ctrough,ss value < 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group. (NCT01452347)
Timeframe: Week 1
Intervention | percentage of participants (Number) |
---|---|
Patients Evaluated | 26.9 |
Percentage of patients with observed Ctrough,ss value < 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group. (NCT01452347)
Timeframe: Week 2
Intervention | percentage of participants (Number) |
---|---|
Patients Evaluated | 19.2 |
Percentage of patients with observed Ctrough,ss value < 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group. (NCT01452347)
Timeframe: Week 4
Intervention | percentage of participants (Number) |
---|---|
Patients Evaluated | 9.8 |
Primary endpoint - Incidence of ARN is the primary outcome of this study and this is based on a documentation of AKI (defined as an increase in baseline serum creatinine ≥ 0.3 mg/dL), in the absence of any other obvious etiology for the AKI identified after a standard clinical evaluation and work up by the patient's primary care physician, cardiologist or nephrologist. This incidence will be expressed as a percentage. (NCT02900170)
Timeframe: 6 months
Intervention | Percentage of participants (Number) |
---|---|
Participants | 0 |
Frequency of patients with possible clinically significant abnormalities. (NCT00680186)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout
Intervention | participants (Number) | |||||
---|---|---|---|---|---|---|
AST increase | AST decrease | ALT increase | ALT decrease | Bilirubin increase | Bilirubin decrease | |
Dabigatran 150 mg | 29 | 0 | 31 | 0 | 8 | 0 |
Warfarin | 27 | 0 | 40 | 0 | 6 | 0 |
Any deaths which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
Intervention | participants (Number) | |
---|---|---|
Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
Dabigatran 150 mg | 25 | 29 |
Warfarin | 25 | 26 |
VTE - related deaths which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. Hazard ratios and 95% CI were not calculated because of insufficient number of events. (NCT00680186)
Timeframe: From randomisation to 6 months (up to day 180) and to end of ptp (planned to be up to day 224)
Intervention | participants (Number) | |
---|---|---|
Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
Dabigatran 150 mg | 3 | 3 |
Warfarin | 0 | 0 |
Any ACS occurring during the conduct of the study (centrally adjudicated as definite). Patients having a centrally adjudicated definite ACS during intake of study drug and after stopping study drug, according to treatment group. ACS assessments pre-specified in the protocol without adjudication. Prior to database lock, the steering committee asked to have ACS events adjudicated by an independent committee. After database lock, the committee was provided with source documentation that was blinded to the patient's treatment assignment. ACS results presented are based on adjudication findings. (NCT00680186)
Timeframe: From first intake of study drug to last contact date
Intervention | participants (Number) | |
---|---|---|
During intake of study drug | After stopping study drug | |
Dabigatran 150 mg | 3 | 2 |
Warfarin | 0 | 1 |
"Major bleeding events (MBE) are defined as~Fatal bleeding~Symptomatic bleeding in a critical area or organ~Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells~Clinically-relevant bleeding events (CRBE) are defined as~spontaneous skin hematoma >=25 cm²~wound hematoma >=100 cm²~spontaneous nose bleed >5 min~macroscopic hematuria spontaneous or >24 hours if associated with an intervention~spontaneous rectal bleeding~gingival bleeding >5 min~leading to hospitalisation and / or requiring surgical treatment~leading to a transfusion of <2 units of whole blood or red cells~any other bleeding event considered clinically relevant by the investigator~Any bleeding events were defined as major, clinically-relevant and nuisance bleeding events. Nuisance bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00680186)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout
Intervention | participants (Number) | ||
---|---|---|---|
MBE | MBE and/or CRBE | Any bleeding event | |
Dabigatran 150 mg | 15 | 64 | 200 |
Warfarin | 22 | 102 | 285 |
Symptomatic DVT which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
Intervention | participants (Number) | |
---|---|---|
Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
Dabigatran 150 mg | 25 | 28 |
Warfarin | 17 | 17 |
Symptomatic fatal and non-fatal PE which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180). For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
Intervention | participants (Number) | |
---|---|---|
Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
Dabigatran 150 mg | 8 | 10 |
Warfarin | 13 | 15 |
Symptomatic non-fatal PE which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180). For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
Intervention | participants (Number) | |
---|---|---|
Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
Dabigatran 150 mg | 7 | 9 |
Warfarin | 13 | 15 |
All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180)
Intervention | participants (Number) | |
---|---|---|
Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
Dabigatran 150 mg | 30 | 34 |
Warfarin | 28 | 30 |
VTE or any death which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
Intervention | participants (Number) | |
---|---|---|
Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
Dabigatran 150 mg | 51 | 57 |
Warfarin | 48 | 51 |
Frequency of patients with possible clinically significant abnormalities. (NCT00291330)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout (washout time can be reduced until 0 day if the patient takes an other anti-coagulant therapy on and after last intake of active study drug)
Intervention | participants (Number) | |||||
---|---|---|---|---|---|---|
AST increase | AST decrease | ALT increase | ALT decrease | Bilirubin increase | Bilirubin decrease | |
Dabigatran 150 mg | 21 | 0 | 26 | 0 | 7 | 0 |
Warfarin | 22 | 0 | 38 | 0 | 13 | 0 |
Any deaths which occured from randomisation to end of post treatment period. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
Intervention | participants (Number) | |
---|---|---|
Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
Dabigatran 150 mg | 21 | 25 |
Warfarin | 21 | 25 |
"VTE - related deaths which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
Intervention | participants (Number) | |
---|---|---|
Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
Dabigatran 150 mg | 1 | 1 |
Warfarin | 3 | 3 |
"Any ACS occurring during the conduct of the study (centrally adjudicated as definite).~Counts of patients having a centrally adjudicated definite ACS during intake of active study drug, after stopping active study drug and before or without intake of active study drug, according to treatment group.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: From first intake of study drug to end of study conduct
Intervention | participants (Number) | ||
---|---|---|---|
During intake of active study drug | After stopping active study drug | Before/without intake of active study drug | |
Dabigatran 150 mg | 5 | 4 | 2 |
Warfarin | 3 | 2 | 0 |
"Major bleeding events (MBE) were defined as~Fatal bleeding~Symptomatic bleeding in a critical area or organ~Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells~Clinically-relevant bleeding events (CRBE) was defined as~spontaneous skin hematoma >=25 cm²~spontaneous nose bleed >5 min~macroscopic hematuria spontaneous or >24 hours if associated with an intervention~spontaneous rectal bleeding (more than spotting on toilet paper)~gingival bleeding >5 min~leading to hospitalisation and / or requiring surgical treatment~leading to a transfusion of <2 units of whole blood or red cells~any other bleeding event considered clinically relevant by the investigator~Any bleeding events were defined as major, clinically-relevant and nuisance bleeding events. Nuisance bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00291330)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout (washout time can be reduced until 0 day if the patient takes an other anti-coagulant therapy on and after last intake of active study drug)
Intervention | participants (Number) | ||
---|---|---|---|
Major bleeding events | MBE and/or CRBE | Any bleeding events | |
Dabigatran 150 mg | 20 | 71 | 207 |
Warfarin | 24 | 111 | 280 |
"Symptomatic DVT which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
Intervention | participants (Number) | |
---|---|---|
Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
Dabigatran 150 mg | 16 | 17 |
Warfarin | 18 | 22 |
"Symptomatic non-fatal PE which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
Intervention | participants (Number) | |
---|---|---|
Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
Dabigatran 150 mg | 13 | 16 |
Warfarin | 7 | 8 |
All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180)
Intervention | Participants (Number) | |
---|---|---|
Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
Dabigatran 150 mg | 30 | 34 |
Warfarin | 27 | 32 |
"VTE or any death which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
Intervention | Participants (Number) | |
---|---|---|
Participants with event (up to day 180) | Participants with event (up to end of ptp) | |
Dabigatran 150 mg | 48 | 55 |
Warfarin | 44 | 53 |
The investigators will calculate the # of gap days between refills for dabigatran/rivaroxaban/apixaban for each3 and 6 months of the pilot intervention. This will be based on pharmacy refill data and calculated using the date dabigatran/rivaroxaban/apixaban was dispensed and the # of days supplied for that prescription. We will add the # of gap days for each 3 and 6 months of the pilot for each patient, and compare the total # of gaps days between intervention and usual care patients. The gap days between refills is a validated measure of adherence and identifies patients with sub-optimal adherence.A negative gap day value indicates that participants received the refill prior to completion of the previous prescription. (NCT01578044)
Timeframe: 3 and 6 months
Intervention | days (Number) | |
---|---|---|
# of Patient gap days for 3-months of intervention | # of Patient gap days for 6-months of intervention | |
Intervention Group | 43 | 41 |
Usual Care Group | 51 | -5 |
Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0-12 hours after the dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose
Intervention | ng/mL (Geometric Mean) |
---|---|
Apixaban 2.5 mg | 59.7 |
Apixaban 5 mg | 97.9 |
Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0-12 hours after the dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose
Intervention | ng/mL (Geometric Mean) |
---|---|
Apixaban 2.5 mg | 28.2 |
Apixaban 5mg | 49.7 |
Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0 to 12 hours after dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose
Intervention | ng*h/mL (Geometric Mean) |
---|---|
Apixaban 2.5 mg | 507 |
Apixaban 5mg | 868 |
"Assess the safety of apixaban versus warfarin regarding ISTH major bleeding or clinically relevant non-major bleeding events in patients with NVAF (nonvalvular atrial fibrillation) and ESRD (end-stage renal disease) on hemodialysis.~Major bleeding event is defined as:Acute clinically overt bleeding (including access site related bleeding) accompanied by 1 or more of the following: Decrease in Hgb of 2g/dL or more with overt bleeding; Transfusion of 2 or more units of packed RBCs in the setting of an overt bleeding event; Bleeding within a critical site. Hemorrhagic stroke (primary or infarction with hemorrhagic conversion) were classified as major bleeds.~Non-major bleeding event is defined as: Acute or sub-acute clinically overt bleeding (including access site related bleeding) that does not meet criteria for major bleeding & results in Hospital admission for bleeding, physician guided medical or surgical treatment for bleeding, or change in antithrombotic therapy" (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
Intervention | Participants (Count of Participants) |
---|---|
Apixaban | 21 |
Warfarin | 16 |
Evaluate mortality rates for those participants randomized to warfarin and apixaban in patients with NVAF and ESRD on hemodialysis (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
Intervention | Participants (Count of Participants) |
---|---|
Apixaban | 21 |
Warfarin | 13 |
"Adjudcated stroke defined as a new, non-traumatic episode of focal or global neurological dysfunction of sudden onset caused by central nervous system (CNS) vascular injury as a result of hemorrhage or infarction and not due to a readily identifiable non-vascular cause (i.e. brain tumor). CNS includes brain, spinal cord and retina. The required duration of the deficit is ≥ 24 hours.~Events with neurologic deficit lasting for < 24 hours and an imaging modality showing evidence of an acute stroke will be counted as stroke as well.~A retinal ischemic event (embolism, infarction) will be considered a stroke" (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
Intervention | Participants (Count of Participants) |
---|---|
Apixaban | 2 |
Warfarin | 2 |
Number of participants experiencing adjudicated stroke or systemic embolism. (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
Intervention | Participants (Count of Participants) |
---|---|
Apixaban | 2 |
Warfarin | 2 |
"Evaluate those experiencing stroke, systemic embolism, ISTH major bleeding, or all-cause mortality for those randomized to warfarin and apixaban in patients with NVAF and ESRD on hemodialysis~Definitions of stroke and systemic embolism are provided under the measurement description of the secondary outcomes for each individual event. Definition of major bleed is provided in outcome measurement description of the primary outcome measure." (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
Intervention | Participants (Count of Participants) |
---|---|
Apixaban | 27 |
Warfarin | 29 |
"Adjudicated diagnosis of systemic arterial embolism (Non-pulmonary, non-cranial events) will require a positive clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), which is supported by evidence of embolism/thrombosis from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.~Clinical presentation would include:~Abrupt development of pain, absent pulses, pallor, and/or paresis in an extremity (at least an entire digit) without previous severe claudication or findings of severe peripheral vascular disease.~Renal embolism will be diagnosed when sudden flank pain or a change in renal laboratory findings occurred.~Abdominal vascular/visceral embolism was considered definite if acute abdominal symptoms or referred symptoms developed along with a change in abdominal examination or appropriate laboratory values." (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
Intervention | Participants (Count of Participants) |
---|---|
Apixaban | 0 |
Warfarin | 0 |
Evaluate days between time from initiation to discontinuation of randomized therapy. (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
Intervention | Days (Mean) |
---|---|
Apixaban | 304.4 |
Warfarin | 279.6 |
Cmin,1 (Minimum concentrations at any time point since the end of first vial of idarucizumab up to 4 hours after the completion of second vial) of unbound sum (free) dabigatran, provided that two vials given not more than 15 min apart in group A and B. (NCT02104947)
Timeframe: Since the end of first vial of idarucizumab up to 4 hours after the completion of second vial
Intervention | ng/mL (Geometric Mean) |
---|---|
Idarucizumab (Group A & B) | 1.12 |
Occurrence of major/life-threatening/fatal bleeding (for group B only) intraoperatively and up to 24 hours post-surgery were classified according to major or life-threatening bleeding (ISTH [International Society for Thrombosis and Hemostasis] definition). 95% Confidence Interval (CI) is from Clopper-Pearson method. (NCT02104947)
Timeframe: within 24 hours of surgery
Intervention | percentage of participants (Number) |
---|---|
Idarucizumab (Group B) | 3.0 |
Time to cessation of bleeding (for Group A only) since first infusion up to 24 hours after the completion of second infusion; bleeding status was to be categorized before and at several time points after treatment. (NCT02104947)
Timeframe: from the first infusion up to 24 hours after the last infusion on Day 1
Intervention | hours (Median) |
---|---|
ICH (Group A) | 10.73 |
Non-ICH (Group A) | 2.49 |
Duration of reversal, defined as the time period a patient remained completely reversed based on dTT or ECT, up to 24 hours or re-starting the treatment of dabigatran. (NCT02104947)
Timeframe: from the first infusion up to 24 hours after the last infusion on Day 1
Intervention | hours (Mean) | |
---|---|---|
ECT (# patients evaluable for reversal=276; 185) | dTT (# patients evaluable for reversal=244; 152) | |
Idarucizumab (Group A) | 13.2 | 19.8 |
Idarucizumab (Group B) | 12.8 | 18.8 |
"Maximum reversal of anticoagulant effect of dabigatran based on central laboratory determination of diluted thrombin time (dTT) or ecarin clotting time (ECT), at any time point from the end of the first infusion up to 4 hours after the last infusion.~Reversal is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% ULN (evaluable patients).~Reversal is calculated as 100* (pre-dose value minus post dose value)/(pre-dose value minus 100% x ULN); if calculated reversal is > 100, it was set to 100." (NCT02104947)
Timeframe: from the end of the first infusion up to 4 hours after the last infusion on Day 1
Intervention | percentage (Median) | |
---|---|---|
dTT (# patients evaluable for reversal=244; 152) | ECT (# patients evaluable for reversal=276; 185) | |
Idarucizumab (Group A) | 100.0 | 100.0 |
Idarucizumab (Group B) | 100.0 | 100.0 |
"Reversal of anticoagulation as measured by diluted Thrombin Time (dTT) or Ecarin Clotting Time (ECT) after the first vial of idarucizumab and before the start of second vial.~Reversal is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% ULN (evaluable patients). Reversal is calculated as 100*(pre-dose value minus post dose value)/(pre-dose value minus 100% x ULN); if calculated reversal is > 100, it was set to 100." (NCT02104947)
Timeframe: after the first vial of idarucizumab and before the start of second vial on Day1
Intervention | percentage (Median) | |
---|---|---|
dTT (# patients evaluable for reversal=240; 150) | ECT (# patients evaluable for reversal=271; 182) | |
Idarucizumab (Group A) | 100.0 | 100.0 |
Idarucizumab (Group B) | 100.0 | 100.0 |
"Reversal of anticoagulation as measured by Activated Partial Thromboplastin Time (aPTT) and Thrombin time (TT), at any time point since the end of first infusion up to 4 hours after the completion of the last infusion. Reversal is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% ULN (evaluable patients).~Reversal is calculated as 100* (pre-dose value minus post dose value)/(pre-dose value minus 100% x ULN); if calculated reversal is > 100, it was set to 100." (NCT02104947)
Timeframe: from the end of the first infusion up to 4 hours after the last infusion on Day 1
Intervention | percentage (Median) | |
---|---|---|
aPTT (# patients evaluable for reversal=232; 141) | TT (# patients evaluable for reversal=278; 188) | |
Idarucizumab (Group A) | 100.0 | 100.0 |
Idarucizumab (Group B) | 100.0 | 100.0 |
All cause death, as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
Intervention | Participants (Number) |
---|---|
Dabigatran 220mg | 0 |
Enoxaparin | 1 |
Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
Intervention | Participants (Number) |
---|---|
Dabigatran 220mg | 18 |
Enoxaparin | 33 |
Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
Intervention | Participants (Number) |
---|---|
Dabigatran 220mg | 17 |
Enoxaparin | 31 |
Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
Intervention | Participants (Number) |
---|---|
Dabigatran 220mg | 1 |
Enoxaparin | 2 |
Symptomatic Deep Vein Thrombosis, confirmed by venous duplex, ultrasound, venography or autopsy, and as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
Intervention | Participants (Number) |
---|---|
Dabigatran 220mg | 0 |
Enoxaparin | 4 |
Total Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
Intervention | Participants (Number) |
---|---|
Dabigatran 220mg | 60 |
Enoxaparin | 67 |
"Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).~All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients." (NCT00657150)
Timeframe: 28-35 days
Intervention | Participants (Number) |
---|---|
Dabigatran 220mg | 61 |
Enoxaparin | 69 |
Volume of blood loss for treated and operated patients during surgery. (NCT00657150)
Timeframe: Day 1
Intervention | mL (Mean) |
---|---|
Dabigatran 220mg | 404.9 |
Enoxaparin | 411.0 |
Number of treated and operated patients with required blood transfusion on day of surgery. (NCT00657150)
Timeframe: Day 1
Intervention | participants (Number) | |
---|---|---|
Transfusions required | Missing | |
Dabigatran 220mg | 246 | 4 |
Enoxaparin | 237 | 7 |
Frequency of patients with possible clinically significant abnormalities. (NCT00657150)
Timeframe: First administration to end of study
Intervention | participants (Number) | |||||
---|---|---|---|---|---|---|
AST increase N=(964;962) | AST decrease N=(964;962) | ALT increase N=(966;962) | ALT decrease N=(966;962) | Bilirubin increase N=(966;962) | Bilirubin decrease N=(966;962) | |
Dabigatran 220mg | 28 | 0 | 34 | 0 | 3 | 0 |
Enoxaparin | 44 | 0 | 67 | 0 | 1 | 0 |
"Major bleeding events were defined as~fatal~clinically overt associated with loss of haemoglobin >=20g/L in excess of what was expected~clinically overt leading to the transfusion of >=2 units packed cells or whole blood in excess of what was expected~symptomatic retroperitoneal, intracranial, intraocular or intraspinal~requiring treatment cessation~leading to re-operation~Clinically-relevant was defined as~spontaneous skin hematoma >=25 cm²~wound hematoma >=100 cm²~spontaneous nose bleed >5 min~macroscopic hematuria spontaneous or >24 hours if associated with an intervention~spontaneous rectal bleeding~gingival bleeding >5 min~any other bleeding event considered clinically relevant by the investigator~Any bleeding events were defined as major, clinically-relevant and minor bleeding events. Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00657150)
Timeframe: 28-35 days
Intervention | Participants (Number) | ||
---|---|---|---|
Major bleeding events | Major and clinically relevant bleeding events | Any bleeding events | |
Dabigatran 220mg | 14 | 37 | 98 |
Enoxaparin | 9 | 29 | 83 |
Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy). (NCT00657150)
Timeframe: 3 months
Intervention | Participants (Number) | ||||
---|---|---|---|---|---|
Total VTE and all-cause mortality | asymptomatic Deep Vein Thrombosis | symptomatic Deep Vein Thrombosis | Pulmonary Embolism | death | |
Dabigatran 220mg | 2 | 0 | 1 | 1 | 0 |
Enoxaparin | 4 | 1 | 0 | 2 | 1 |
104 reviews available for beta-alanine and Bleeding
Article | Year |
---|---|
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabiga | 2018 |
Managing new oral anticoagulants in the perioperative and intensive care unit setting.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Critical Care; Dabigatran; Hemor | 2013 |
The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Disease Management | 2014 |
Dabigatran: life-threatening bleeding.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Interactions; | 2013 |
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Topics: Administration, Oral; Aging; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; bet | 2013 |
A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
Topics: Administration, Oral; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Antithrombin | 2013 |
Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Disease Progression; Fibrinolytic | 2013 |
Reversal of oral anticoagulation.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabi | 2013 |
Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clini | 2013 |
Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran | 2013 |
[Direct oral thrombin inhibitor, "dabigatran"].
Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2013 |
Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; C | 2013 |
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatr | 2013 |
Managing bleeding in anticoagulated patients in the emergency care setting.
Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; He | 2013 |
Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Ben | 2013 |
Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chronic Disease; Dabigatran; Drug | 2014 |
Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; | 2013 |
Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; | 2013 |
The perioperative management of new direct oral anticoagulants: a question without answers.
Topics: Administration, Oral; Aged; Anesthesiology; Anticoagulants; Arthroplasty, Replacement, Hip; Arthropl | 2013 |
Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug O | 2013 |
Dabigatran and kidney disease: a bad combination.
Topics: Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Blood Coagulation | 2013 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpr | 2013 |
Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug | 2013 |
Bleeding and antidotes in new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabig | 2013 |
[Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Emergencies; Emergency Medical Services; F | 2013 |
Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; | 2013 |
Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
Topics: Antibodies; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Clinical Trials | 2013 |
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; | 2014 |
{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Fact | 2014 |
Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Global Health; Hemorrh | 2014 |
New antithrombotics for secondary prevention of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Cor | 2014 |
New oral anticoagulant agents - general features and outcomes in subsets of patients.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as To | 2014 |
Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.
Topics: Acute Disease; Administration, Oral; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials, P | 2014 |
Practical considerations in emergency management of bleeding in the setting of target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Emerg | 2014 |
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzi | 2014 |
Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interaction | 2014 |
Risk of major bleeding and the standard doses of dabigatran.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Ra | 2014 |
The newer direct oral anticoagulants: a practical guide.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2014 |
New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; | 2014 |
Anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; M | 2014 |
Anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; M | 2014 |
Anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; M | 2014 |
Anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; M | 2014 |
Anticoagulation: a GP primer on the new oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atri | 2014 |
Newer clinically available antithrombotics and their antidotes.
Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Elec | 2014 |
Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; | 2014 |
Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Chi-Square Distribution; Dabigat | 2014 |
Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; | 2014 |
Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Clinical Trials as Topic; D | 2014 |
Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Evi | 2014 |
Management of hemorrhage with the target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Transfusion; Charcoal; Dab | 2014 |
Balancing ischaemia and bleeding risks with novel oral anticoagulants.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; | 2014 |
[Bleeding complications under oral anticoagulation].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigat | 2014 |
Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
Topics: Administration, Oral; Antithrombins; Azepines; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; | 2015 |
Strategies for urgent reversal of target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Charc | 2014 |
Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relati | 2014 |
Reversal of the novel oral anticoagulants dabigatran, rivoraxaban, and apixaban.
Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Coagulants; Dabigatran; Factor Xa I | 2015 |
[Anticoagulant therapy in secondary prevention of coronary events].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine | 2014 |
Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, R | 2015 |
Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation | 2015 |
[Prophylaxis of thromboembolism in atrial fibrillation: new oral anticoagulants and left atrial appendage closure].
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; | 2015 |
Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; He | 2010 |
Managing bleeding complications in patients treated with the old and the new anticoagulants.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor VIIa; Fondaparinux; Hemorrhage; Hep | 2010 |
Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Factor Xa Inhib | 2011 |
New anticoagulants: pharmacology and clinical studies.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation | 2011 |
Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Evidence-Based | 2011 |
New anticoagulants: how to deal with treatment failure and bleeding complications.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Rivaroxab | 2011 |
Anticoagulating obese patients in the modern era.
Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dab | 2011 |
Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Hemorrhage; Human | 2011 |
Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2011 |
Preventing cardioembolic stroke in atrial fibrillation with dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as | 2012 |
Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor.
Topics: Anesthesia, Conduction; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chemistry | 2011 |
[Dabigatran eteksilat new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu | 2011 |
ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigat | 2012 |
A new generation of oral direct anticoagulants.
Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimi | 2012 |
The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.
Topics: Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta | 2012 |
Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; I | 2012 |
[New antithrombotic drugs].
Topics: Adenosine; Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans | 2012 |
[Dabigatran and emergency operation on a peritonitis patient].
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dialysis; Emergency Treatment; Factor VIIa; | 2012 |
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogr | 2012 |
[Prophylaxis of stroke and embolisms in atrial fibrillation--what is new in the guidelines?].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Eviden | 2012 |
New oral anticoagulants: will they replace warfarin?
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Hypersensitivit | 2012 |
[Prevention of cardioembolic stroke].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Doubl | 2012 |
[Clinical management of the new anticoagulants].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Clinic | 2012 |
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazole | 2012 |
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Tri | 2012 |
Complications of anticoagulation.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Contamination; | 2012 |
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2012 |
Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Tech | 2012 |
Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2012 |
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Elective Surgical Pr | 2012 |
Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, R | 2012 |
What did we learn from new oral anticoagulant treatment?
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; B | 2012 |
Antithrombotic treatment of atrial fibrillation: new insights.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2012 |
Laboratory tests and the new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagula | 2012 |
[Anticoagulant therapy in connection with cardioversion in patients with atrial fibrillation].
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coa | 2012 |
Management of dabigatran-induced anticoagulation in trauma and acute care surgery patients.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Woun | 2012 |
[Clinical pharmacological aspects of new oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cytochrome P-450 CYP3A; Cytochro | 2012 |
New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran.
Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2012 |
Acute management of bleeding in patients on novel oral anticoagulants.
Topics: Acute Disease; Administration, Oral; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alani | 2013 |
Perioperative management of patients on chronic antithrombotic therapy.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic A | 2012 |
[New anticoagulants--are we prepared?].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; | 2012 |
[Pharmacovigilance update].
Topics: Adrenergic Uptake Inhibitors; Age Factors; Aged; Amides; Antihypertensive Agents; Atomoxetine Hydroc | 2013 |
Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Emerge | 2013 |
Thrombin inhibitors: surgical considerations and pharmacology.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatr | 2013 |
21 trials available for beta-alanine and Bleeding
Article | Year |
---|---|
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow | 2013 |
Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2013 |
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2013 |
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2013 |
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2013 |
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2013 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpr | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; | 2014 |
Warfarin or dabigatran for treatment of atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Europe; Hemorrh | 2014 |
Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, F | 2014 |
[Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibi | 2014 |
Idarucizumab for Dabigatran Reversal.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Anticoagulants; Benzimidazoles; beta-Ala | 2015 |
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; bet | 2010 |
Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Echocardiography, Tra | 2011 |
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimida | 2011 |
Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Benzimidazoles; beta-Ala | 2011 |
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose- | 2011 |
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alan | 2011 |
Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2011 |
Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Respons | 2012 |
Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazol | 2012 |
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain I | 2012 |
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain I | 2012 |
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain I | 2012 |
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain I | 2012 |
176 other studies available for beta-alanine and Bleeding
Article | Year |
---|---|
Case Report: Intracorneal Hemorrhages Seen with Scleral Contact Lens Wear and Netarsudil Therapy.
Topics: Aged; Benzoates; beta-Alanine; Contact Lenses; Glaucoma, Open-Angle; Hemorrhage; Humans; Male; Scler | 2022 |
Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as | 2013 |
Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; C | 2013 |
Dabigatran and postmarketing reports of bleeding.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Gastrointestinal Hemorrhage | 2013 |
Letter by David et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) Randomized Trial".
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Thromboembolism; War | 2013 |
Letter by Hjemdahl et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial".
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Thromboembolism; War | 2013 |
Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin.
Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzi | 2013 |
Venous thromboembolism: prophylactic and therapeutic practice guideline.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Chemoprevention; Dabigatran; Disease Management; Dose- | 2013 |
[Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Benzimidazoles; beta-Alanine; C | 2013 |
The use, misuse and abuse of dabigatran.
Topics: Advertising; Anticoagulants; Antithrombins; Aspirin; Australia; Benzimidazoles; beta-Alanine; Cardio | 2013 |
Is there really misuse and abuse of dabigatran?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Myocard | 2013 |
Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Lung | 2013 |
Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation.
Topics: Age Factors; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular | 2013 |
New approaches to reversing oral anticoagulant therapy. Introduction.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-A | 2013 |
Pharmacologic interventions for reversing the effects of oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-A | 2013 |
Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Thromboembolism; War | 2013 |
Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice.
Topics: Age Factors; Aged; Antithrombins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fi | 2013 |
Dabigatran and bleeding: still an emergent situation?
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Coagulants; Dabigatran; Factor VIIa; Factor VI | 2013 |
Uncontrollable haemorrhage following dabigatran prophylaxis.
Topics: Abdomen; Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Emergency | 2013 |
The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dr | 2013 |
Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation".
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; | 2013 |
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.".
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabet | 2013 |
Dabigatran and mechanical valves: less effective and more risky than warfarin.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Prosthesis; Heart Valve Prosth | 2013 |
Adherence to anticoagulant treatment with dabigatran in a real-world setting.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; b | 2013 |
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; | 2013 |
[New anticoagulants, new emergencies?].
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Female; Hemorr | 2013 |
Dabigatran monitoring made simple?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation | 2013 |
Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cardiac Pacing, Artificial; D | 2013 |
Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Data Collection; Female; He | 2013 |
Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
The promise of pharmacoepidemiology in helping clinicians assess drug risk.
Topics: Administration, Oral; Advertising; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine | 2013 |
Reversal of a dabigatran overdose: what are possible options?
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Coagulants; Dabigatran; Factor VIIa; Hemorrhag | 2013 |
Dabigatran - neurosurgical anathema?
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Male; Risk Assess | 2013 |
Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats.
Topics: Acute Kidney Injury; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatra | 2014 |
The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran | 2013 |
Fatal bleeding associated with dabigatran.
Topics: Aged; Benzimidazoles; beta-Alanine; Dabigatran; Fatal Outcome; Female; Hemorrhage; Humans | 2013 |
Anticoagulation without monitoring.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hemorrhage; Heparin; Huma | 2013 |
Intravenous lipid emulsion does not reverse dabigatran-induced anticoagulation in a rat model.
Topics: Administration, Oral; Animals; Antithrombins; Benzimidazoles; beta-Alanine; Bleeding Time; Blood Coa | 2013 |
Use of prothrombin complex concentrates for urgent reversal of dabigatran in the Emergency Department.
Topics: Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors; | 2013 |
Renal risk stratification with the new oral anticoagulants (July 2013).
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; | 2013 |
A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Da | 2014 |
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Ben | 2013 |
[Prevention and treatment of major bleeding during anticoagulation].
Topics: Administration, Oral; Alcohol Drinking; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Hemor | 2013 |
Evaluation of dabigatran exposures reported to poison control centers.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; | 2014 |
Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; D | 2014 |
In reply.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; | 2013 |
Direct oral anticoagulants for acute venous thromboembolism: closing the circle?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; | 2014 |
[Experience with rivaroxaban and dabigatran].
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Therapy, Combination; | 2013 |
Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation | 2014 |
[Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery].
Topics: Acute Kidney Injury; Aged, 80 and over; Alzheimer Disease; Antithrombins; Atrial Fibrillation; Benzi | 2014 |
Activated prothrombin complex concentrate for dabigatran-associated bleeding.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Brain; Dabigatran; Female; Hematoma, | 2014 |
How I treat target-specific oral anticoagulant-associated bleeding.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-A | 2014 |
Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2014 |
Impaired renal function and bleeding in elderly treated with dabigatran.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2014 |
Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2014 |
[Extrapolation of physiopathological data to clinical practice: Example of dabigatran in off-label use].
Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Contraindications; Dabigatr | 2014 |
Fatal dabigatran-associated bleeding.
Topics: Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans | 2014 |
Fatal dabigatran-associated bleeding.
Topics: Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans | 2014 |
Translational insights into traumatic brain injury occurring during dabigatran or warfarin anticoagulation.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors; | 2014 |
Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cathe | 2014 |
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clini | 2014 |
Activated prothrombin complex concentrate for the prevention of dabigatran-associated bleeding.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatra | 2014 |
Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Ben | 2014 |
ACP Journal Club. Review: Dabigatran does not differ from vitamin K antagonists for mortality or major bleeding.
Topics: Benzimidazoles; beta-Alanine; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Thromboembo | 2014 |
Perioperative management of patients on new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological | 2014 |
[Not Available].
Topics: Benzimidazoles; beta-Alanine; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Thromboembo | 2014 |
Evidence suggests dabigatran is an effective and safe treatment for patients with VTE requiring early parenteral therapy.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Venou | 2014 |
Direct oral anticoagulants--pharmacology, drug interactions, and side effects.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; D | 2014 |
Direct oral anticoagulants in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2014 |
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort St | 2014 |
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort St | 2014 |
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort St | 2014 |
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort St | 2014 |
Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors; Dabigatra | 2014 |
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu | 2014 |
Dabigatran: how the drug company withheld important analyses.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Drug Appr | 2014 |
The trouble with dabigatran.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Drug Appr | 2014 |
Concerns over data in key dabigatran trial.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Dose-Resp | 2014 |
Dabigatran, bleeding, and the regulators.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Dose-Response Rel | 2014 |
Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fees, Pharmaceutical; Health Expenditures; | 2014 |
Continuation of dabigatran therapy in "real-world" practice in Hong Kong.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2014 |
Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2014 |
Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants.
Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies | 2015 |
Dabigatran in secondary stroke prevention: clinical experience with 106 patients.
Topics: Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Female; Hemorrhag | 2014 |
Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Health | 2014 |
Dabigatran: patient management in specific clinical settings.
Topics: Antithrombins; Arthroplasty, Replacement; Austria; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrh | 2014 |
[New oral anticoagulants are as safe in elderly patients as conventional drugs].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; H | 2014 |
[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu | 2014 |
Letter by Hifumi et al regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin".
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Venous Thromboe | 2014 |
Response to letter regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin".
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Venous Thromboe | 2014 |
[Eligibility for dabigatran therapy: the real-life experience of a Tuscany general hospital].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2014 |
Additional events in the RE-LY trial.
Topics: Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Randomized Controlled Trials as Topic; | 2014 |
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles | 2015 |
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles | 2015 |
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles | 2015 |
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles | 2015 |
The importance of postapproval data for dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female | 2015 |
Risk of bleeding with dabigatran in atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidaz | 2015 |
A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbid | 2014 |
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alani | 2014 |
Atrial fibrillation: Risk of bleeding with dabigatran versus warfarin particularly high in CKD.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage | 2015 |
Intermittent haemodialysis and continuous veno-venous dialysis are effective in mitigating major bleeding due to dabigatran.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Male | 2015 |
CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough.
Topics: Adolescent; Adult; Aged; Algorithms; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazo | 2015 |
[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coa | 2014 |
Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; | 2015 |
Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Factor VIIa; He | 2015 |
Managing bleeding and emergency reversal of newer oral anticoagulants: a review for primary care providers.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemor | 2014 |
Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cathe | 2015 |
[Advantages and disadvantages of warfarin and pradaxa therapy for venous thromboembolism].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Dose-Response Relations | 2014 |
[Retrospective study about 73 consecutive patients treated by direct oral anticoagulant and admitted to an emergency room].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr | 2015 |
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr | 2015 |
[Extended options of anticoagulant treatment in thromboembolism].
Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Czech Republic; Dabigatran; | 2014 |
Gastrointestinal bleeding. Gastrointestinal bleeding risk is increased by novel anticoagulants.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage | 2015 |
[Dabigatran and risk of bleeding].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage | 2015 |
Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran.
Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagu | 2015 |
What is the role of hemodialysis for dabigatran-associated major bleeding?
Topics: Aged; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Male; Observational Studies as T | 2014 |
Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit).
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; | 2015 |
[New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Drug Substitution; Half-L | 2015 |
[Triple anticoagulant therapy - now what can I give for pain?].
Topics: Aged; Analgesics; Anticoagulants; Aspirin; Back Pain; Benzimidazoles; beta-Alanine; Clopidogrel; Con | 2015 |
[Antidote to dabigatran].
Topics: Antibodies, Monoclonal, Humanized; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Ris | 2015 |
Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindic | 2015 |
Perioperative Management of Dabigatran: A Prospective Cohort Study.
Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Di | 2015 |
Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatr | 2015 |
Complications With New Oral Anticoagulants Dabigatran and Rivaroxaban in Cutaneous Surgery.
Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dermatologic Su | 2015 |
Targeted Anti-Anticoagulants.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Benzimidazoles; beta-Alanine; Female; Hemorrhage; | 2015 |
One-Year Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation: Placing Real-World Results Into Perspective.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage | 2015 |
Bleeding in Patients of African Ancestry Using Dabigatran: A Potential Effect of Creatine Kinase.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage | 2015 |
The Role of Selection in the Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage | 2015 |
A Methodological Appraisal of Recent Real-World Data Publications on Dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage | 2015 |
Dosage of Dabigatran as a Risk Factor for Bleeding in Atrial Fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage | 2015 |
Patient Characteristics and Risk of Bleeding With Dabigatran in Atrial Fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage | 2015 |
Risk of Bleeding With Dabigatran in 2010-2011 Medicare Data.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage | 2015 |
Dabigatran (Pradaxa): deep vein thrombosis and pulmonary embolism. Warfarin remains the standard drug.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagula | 2015 |
Letter by Lavine Regarding Article, "Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation".
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Hemorrhage; Humans; Medicare; War | 2015 |
Bleeding risk higher with rivaroxaban than dabigatran for stroke prevention, head-to-head trial shows.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2016 |
Complications With New Oral Anticoagulants Dabigatran and Rivaroxaban in Cutaneous Surgery.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Dermatologic Surgica | 2017 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Ben | 2011 |
Warfarin or not.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Pulmonary Embolism; Ve | 2010 |
Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Emboli | 2011 |
Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran.
Topics: Aged; Antithrombins; Aphasia; Benzimidazoles; beta-Alanine; Carotid Artery Diseases; Dabigatran; Fem | 2011 |
Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefi | 2011 |
Ask the doctor. For several years, I have been taking warfarin because of atrial fibrillation. I recently suffered several nosebleeds, which took two days to control. The trauma of those episodes makes me want to swear off warfarin, but I am not sure what
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Health Knowledge | 2011 |
Dabigatran in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Creatinine; Dabigatran; Dose-Resp | 2011 |
[New anticoagulants: "efficacy and safety" or "efficacy or safety"].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans | 2011 |
Dabigatran for stroke prevention in all patients with atrial fibrillation?
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr | 2011 |
The use of dabigatran immediately after atrial fibrillation ablation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; | 2012 |
Lack of an antagonist to reverse the action of dabigatran.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Hemorrhage; Hum | 2012 |
Learning the respective roles of warfarin and dabigatran to prevent stroke in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Fema | 2011 |
Acutely injured patients on dabigatran.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Thrombelastography; Wh | 2011 |
Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Fe | 2012 |
Letter by Govindarajan and Salgado regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; | 2012 |
Letter by Reynolds et al regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) tri
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; | 2012 |
Letter by Reiffel regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; | 2012 |
Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatr | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Dabigatran (Pradaxa).
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrha | 2012 |
More on acutely injured patients receiving dabigatran.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Hemorrhage; Humans; Wounds and Injuries | 2012 |
Bleeding risk with dabigatran in the frail elderly.
Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Frail Elderly; Hem | 2012 |
Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; | 2012 |
Clinical challenges in a patient with dabigatran-induced fatal hemorrhage.
Topics: Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fatal Outcome; Female; Hemorrhage; H | 2012 |
Avoiding adverse events with dabigatran by careful selection of eligible patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contr | 2012 |
Dabigatran versus warfarin after mechanical mitral valve replacement in the swine model.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Evaluation, Preclinical; Fem | 2012 |
Anticoagulation, novel agents, and procedures: can we pardon the interruption?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Thromboe | 2012 |
Dabigatran: uncharted waters and potential harms.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemor | 2012 |
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clini | 2012 |
Factors influencing doctors' selection of dabigatran in non-valvular atrial fibrillation.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Eligibility De | 2013 |
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazo | 2012 |
The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis.
Topics: Aged, 80 and over; Anemia; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigat | 2013 |
A comparison of bleeding complications post-ablation between warfarin and dabigatran.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Abl | 2012 |
Hemorrhagic complications associated with dabigatran use.
Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage | 2012 |
Diffuse alveolar hemorrhage associated with dabigatran.
Topics: Aged; Antithrombins; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Dabigatran; | 2012 |
A 77-year-old man with a prolonged activated partial thromboplastin time.
Topics: Aged; Anticoagulants; Autoantibodies; Benzimidazoles; beta-Alanine; Dabigatran; Diagnosis, Different | 2012 |
Vascular insult accompanied by overexpressed heme oxygenase-1 as a pathophysiological mechanism in experimental neurolathyrism with hind-leg paraparesis.
Topics: Animals; beta-Alanine; Blood Vessels; Disease Models, Animal; Heme Oxygenase-1; Hemorrhage; Human Um | 2012 |
Periprocedural anticoagulant management.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Coronary Restenosis; Dabigatran; Heart | 2012 |
Faculty of Consulting Physicians of South Africa (FCPSA): saving brain with dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; I | 2012 |
Editorial critique.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Woun | 2012 |
Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2013 |
[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidaz | 2012 |
Transitions of care in anticoagulation management for patients with atrial fibrillation.
Topics: Administration, Oral; Aftercare; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Ala | 2012 |
Acute adrenal failure following anticoagulation with dabigatran after hip replacement and thrombolysis for massive pulmonary embolism.
Topics: Adrenal Gland Diseases; Adrenal Insufficiency; Aged; Antithrombins; Arthroplasty, Replacement, Hip; | 2013 |
When dabigatran and trauma collide.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Dabigat | 2013 |
[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazole | 2012 |